@article{REID2015424,
title = {Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model},
journal = {Neuroscience},
volume = {298},
pages = {424-435},
year = {2015},
issn = {0306-4522},
doi = {https://doi.org/10.1016/j.neuroscience.2015.04.039},
url = {https://www.sciencedirect.com/science/article/pii/S0306452215003802},
author = {G. Andrew Reid and Sultan Darvesh},
keywords = {Alzheimer’s disease, β-amyloid, butyrylcholinesterase, 5XFAD mouse, butyrylcholinesterase-knockout, cholinergic system},
abstract = {In Alzheimer’s disease (AD), numerous β-amyloid (Aβ) plaques are associated with butyrylcholinesterase (BChE) activity, the significance of which is unclear. A mouse model, containing five human familial AD genes (5XFAD), also develops Aβ plaques with BChE activity. Knock-out of BChE in this model showed diminished fibrillar Aβ plaque deposition, more so in males than females. This suggests that lack of BChE reduces deposition of fibrillar Aβ in AD and this effect may be influenced by sex.}
}
@article{KRATKY2018668,
title = {Investigation of salicylanilide and 4-chlorophenol-based N-monosubstituted carbamates as potential inhibitors of acetyl- and butyrylcholinesterase},
journal = {Bioorganic Chemistry},
volume = {80},
pages = {668-673},
year = {2018},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2018.07.017},
url = {https://www.sciencedirect.com/science/article/pii/S0045206818305728},
author = {Martin Krátký and Šárka Štěpánková and Katarína Vorčáková and Jarmila Vinšová},
keywords = {Acetylcholinesterase, Butyrylcholinesterase, Carbamate, Enzyme inhibition,  inhibition, Salicylanilide},
abstract = {Based on the presence of carbamate moiety, twenty salicylanilide N-monosubstituted carbamates concomitantly with their parent salicylanilides and five newly prepared 4-chlorophenyl carbamates obtained from isocyanates were investigated using Ellman’s method for their in vitro inhibitory activity against acetylcholinesterase (AChE) from electric eel and butyrylcholinesterase (BChE) from equine serum. The carbamates and salicylanilides exhibited mostly a moderate inhibition of both cholinesterase enzymes with IC50 values ranging from 5 to 235 µM. IC50 values for AChE were in a narrower concentration range when compared to BChE, but many of the compounds produced a balanced inhibition of both cholinesterases. The derivatives were comparable or superior to rivastigmine for AChE inhibition, but only a few of carbamates also for BChE. Several structure-activity relationships were identified, e.g., N-phenethylcarbamates produce clearly favourable BChE inhibition. The compounds also share convenient physicochemical properties for CNS penetration.}
}
@article{SHENOUDA2009135,
title = {An evaluation of the inhibition of human butyrylcholinesterase and acetylcholinesterase by the organophosphate chlorpyrifos oxon},
journal = {Toxicology and Applied Pharmacology},
volume = {241},
number = {2},
pages = {135-142},
year = {2009},
issn = {0041-008X},
doi = {https://doi.org/10.1016/j.taap.2009.08.014},
url = {https://www.sciencedirect.com/science/article/pii/S0041008X09003500},
author = {Josephine Shenouda and Paula Green and Lester Sultatos},
keywords = {Acetylcholinesterase, Butyrylcholinesterase, Chlorpyrifos oxon, Organophosphate insecticides, Pesticides},
abstract = {Acetylcholinesterase (EC 3.1.1.7) and butyrylcholinesterase (EC 3.1.1.8) are enzymes that belong to the superfamily of α/β-hydrolase fold proteins. While they share many characteristics, they also possess many important differences. For example, whereas they have about 54% amino acid sequence identity, the active site gorge of acetylcholinesterase is considerably smaller than that of butyrylcholinesterase. Moreover, both have been shown to display simple and complex kinetic mechanisms, depending on the particular substrate examined, the substrate concentration, and incubation conditions. In the current study, incubation of butyrylthiocholine in a concentration range of 0.005–3.0 mM, with 317 pM human butyrylcholinesterase in vitro, resulted in rates of production of thiocholine that were accurately described by simple Michaelis–Menten kinetics, with a Km of 0.10 mM. Similarly, the inhibition of butyrylcholinesterase in vitro by the organophosphate chlorpyrifos oxon was described by simple Michaelis–Menten kinetics, with a ki of 3048 nM−1 h−1, and a KD of 2.02 nM. In contrast to inhibition of butyrylcholinesterase, inhibition of human acetylcholinesterase by chlorpyrifos oxon in vitro followed concentration-dependent inhibition kinetics, with the ki increasing as the inhibitor concentration decreased. Chlorpyrifos oxon concentrations of 10 and 0.3 nM gave kis of 1.2 and 19.3 nM−1 h−1, respectively. Although the mechanism of concentration-dependent inhibition kinetics is not known, the much smaller, more restrictive active site gorge of acetylcholinesterase almost certainly plays a role. Similarly, the much larger active site gorge of butyrylcholinesterase likely contributes to its much greater reactivity towards chlorpyrifos oxon, compared to acetylcholinesterase.}
}
@article{SAXENA20181607,
title = {Tetramer organizing polyproline-rich peptides identified by mass spectrometry after release of the peptides from Hupresin-purified butyrylcholinesterase tetramers isolated from milk of domestic pig (Sus scrofa)},
journal = {Data in Brief},
volume = {20},
pages = {1607-1619},
year = {2018},
issn = {2352-3409},
doi = {https://doi.org/10.1016/j.dib.2018.08.109},
url = {https://www.sciencedirect.com/science/article/pii/S2352340918309612},
author = {Ashima Saxena and Tatyana Belinskaya and Lawrence M. Schopfer and Oksana Lockridge},
abstract = {Milk of the domestic pig has 10 times more butyrylcholinesterase (BChE) per mL than porcine serum. We purified BChE from porcine milk by affinity chromatography on Hupresin-Sepharose. The pure porcine BChE (PoBChE) was a tetramer with a molecular weight of 340,000, similar to that of human BChE tetramers. The C-terminal 40 residues of PoBChE constitute the tetramerization domain. The glue that holds the 4 BChE subunits together is a polyproline-rich peptide. Mass spectrometry analysis of trypsin-digested PoBChE identified a variety of polyproline-rich peptides originating from 12 different proteins. The donor proteins exist in the nucleus or cytoplasm of cells and contribute their polyproline-rich peptides after a cell is degraded. The secreted PoBChE scavenges the polyproline-rich peptides and incorporates one polyproline peptide per PoBChE tetramer, where the polyproline peptide is bound noncovalently but very tightly with an estimated dissociation constant of 10–12 M. The most abundant polyproline-rich peptides were derived from acrosin, homeobox protein HoxB4, lysine-specific demethylase 6B, proline-rich protein 12, and proline-rich membrane anchor 1 (PRiMA). The research article associated with the data in this report can be found in Saxena et al. (2018). The Data in Brief report lists all the polyproline-rich peptides identified in PoBChE tetramers.}
}
@article{WILLIAMS2019126754,
title = {Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening},
journal = {Bioorganic & Medicinal Chemistry Letters},
volume = {29},
number = {24},
pages = {126754},
year = {2019},
issn = {0960-894X},
doi = {https://doi.org/10.1016/j.bmcl.2019.126754},
url = {https://www.sciencedirect.com/science/article/pii/S0960894X19307176},
author = {Alexander Williams and Shuo Zhou and Chang-Guo Zhan},
keywords = {Butyrylcholinesterase, Acetylcholinesterase, Inhibitor, Pharmacophore, Docking},
abstract = {Cholinesterase inhibitors have long been used in the treatment of Alzheimer’s Disease (AD) via the protection of acetylcholine levels. However, recent research has shown that the specific inhibition of butyrylcholinesterase (BChE) could better ameliorate symptoms within patients. In addition, it has recently been shown that selective inhibition of BChE can also significantly attenuate the toxicity and physiological effects of heroin. Currently, there are no specific and potent inhibitors of BChE approved for use in AD or heroin abuse. Through a combined use of in silico and in vitro screening, we have found three compounds with sub-50 nM IC50 values that specifically target BChE. These newly discovered BChE inhibitors can act as the lead scaffolds for future development of the desirably potent and selective BChE inhibitors.}
}
@article{BURMAOGLU2019191,
title = {Synthesis and biological evaluation of novel tris-chalcones as potent carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and α-glycosidase inhibitors},
journal = {Bioorganic Chemistry},
volume = {85},
pages = {191-197},
year = {2019},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2018.12.035},
url = {https://www.sciencedirect.com/science/article/pii/S0045206818315013},
author = {Serdar Burmaoglu and Ali Osman Yilmaz and M. Fatih Polat and Rüya Kaya and İlhami Gulcin and Oztekin Algul},
keywords = {Tris-chalcone, Carbonic anhydrase, α-glycosidase, Acetylcholinesterase, Butyrylcholinesterase},
abstract = {A novel class of fluoro-substituted tris-chalcones derivatives (5a-5i) was synthesized from phloroglucinol and corresponding benzaldehydes. A three step synthesis method was followed for the production of these tris-chalcone compounds. The structures of the newly synthesized compounds (5a-5i) were confirmed on the basis of IR, 1H NMR, 13C NMR, and elemental analysis.The compounds’ inhibitory activities were tested against human carbonic anhydrase I and II isoenzymes (hCA I and hCA II), acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase (α-Gly). These chalcone derivatives had Ki values in the range of 19.58–78.73 nM for hCA I, 12.23–41.70 nM for hCA II, 1.09–6.84 nM for AChE, 8.30–32.30 nM for BChE and 0.93 ± 0.20–18.53 ± 5.06 nM against α-glycosidase. These results strongly support the promising nature of the tris-chalcone scaffold as selective carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase, and α-glycosidase inhibitor. Overall, due to these derivatives’ inhibitory potential on the tested enzymes, they are promising drug candidates for the treatment of diseases like glaucoma, leukemia, epilepsy; Alzheimer’s disease; type-2 diabetes mellitus that are associated with high enzymatic activity of carbonic anhydrase, acetylcholine esterase, butyrylcholinesterase, and α-glycosidase.}
}
@article{BARMAK201995,
title = {Antibacterial studies of hydroxyspiro[indoline-3,9-xanthene]trione against spiro[indoline3,9-xanthene]trione and their use as acetyl and butyrylcholinesterase inhibitors},
journal = {Microbial Pathogenesis},
volume = {130},
pages = {95-99},
year = {2019},
issn = {0882-4010},
doi = {https://doi.org/10.1016/j.micpath.2019.03.002},
url = {https://www.sciencedirect.com/science/article/pii/S0882401018310957},
author = {Alireza Barmak and Khodabakhsh Niknam and Gholamhossein Mohebbi and Hamid Pournabi},
keywords = {Xanthenes, Antimicrobial, Anticholinesterases activities, Docking studies, Alzheimer's disease},
abstract = {Xanthene derivatives are well known for their effective biological activities. In search of effective antibacterial agents, the spiro[indoline3,9-xanthene]-trione (A) and hydroxy-spiro[indoline-3,9-xanthene]-trione (B), were synthesized and tested for in vitro antibacterial activity against Staphylococcus aureus and Escherichia coli. Furthermore, the synthesized compounds were tested in vitro and in silico for their anticholinesterase activities. The anticholinesterase activities for six substitutes of the hydroxy derivative (B1-B6) were also studied through the molecular docking. All concentrations of compounds presented a dose-dependent antibacterial activity. The docking results showed that all compounds are more constant than the galantamine. Amongst, compound B1 exhibited the minimum binding energy in both AChE and BChE enzymes. Results indicate the importance of xanthene derivatives as potential antibacterial and anticholinesterases agents.}
}
@article{EID201870,
title = {Attenuated Total Reflectance Fourier Transformation Infrared spectroscopy fingerprinted online monitoring of the kinetics of circulating Butyrylcholinesterase enzyme during metabolism of bambuterol},
journal = {Analytica Chimica Acta},
volume = {1005},
pages = {70-80},
year = {2018},
issn = {0003-2670},
doi = {https://doi.org/10.1016/j.aca.2017.12.011},
url = {https://www.sciencedirect.com/science/article/pii/S0003267017314228},
author = {Sherif M. Eid and Mohamed K. {Abd El-Rahman} and Mohamed R. Elghobashy and Khadiga M. Kelani},
keywords = {ATR FTIR, Online enzyme monitoring, Butyrylcholinesterase, Bambuterol, Terbutaline},
abstract = {We have described a continuous flow ATR-FTIR method for measuring some of the Butyrylcholinesterase enzyme kinetics (Km and Vmax). This is done by developing a circulating system to be close as much as possible to the human circulation using human serum as a source of the enzyme with adjusted pH, isotonicity and temperature to give the maximum affinity of the enzyme towards its substrate (bambuterol). The experiment was running continuously for 90 min to monitor the production of terbutaline from the zero time of its appearance with a measured spectrum in each minute using ZnSe prism. The method was selective and successful for determination of Vmax to be 8.16 × 10−8 mol/min/ml and Km to be 2.28 × 10−5 mol, showing high affinity of the enzyme towards its prodrug substrate Bambuterol. This study critically probes the quantitative ability of the ATR-FTIR method for terbutaline, which was validated according to ICH guidelines showing high accuracy 100.39% and high selectivity towards the produced terbutaline, as the produced spectrums considered as fingerprint of each compound.}
}
@article{DEBAY2019P760,
title = {SYNTHESIS AND IN VIVO BRAIN PET EVALUATION OF 1-METHYL-4-PIPERIDYL P-18[F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASE-SPECIFIC RADIOLIGAND FOR ALZHEIMER’S DISEASE},
journal = {Alzheimer's & Dementia},
volume = {15},
number = {7, Supplement },
pages = {P760},
year = {2019},
note = {Alzheimer’s Association International Conference 2019},
issn = {1552-5260},
doi = {https://doi.org/10.1016/j.jalz.2019.06.2809},
url = {https://www.sciencedirect.com/science/article/pii/S1552526019329590},
author = {Drew R. DeBay and Ian Pottie and Andrew G. Reid and Earl Martin and Antoun Boulaouz and Steve Burrell and Chris V. Bowen and Sultan Darvesh}
}
@article{ERALPINAN2019290,
title = {Serum choline and butyrylcholinesterase changes in response to endotoxin in calves receiving intravenous choline administration},
journal = {Research in Veterinary Science},
volume = {125},
pages = {290-297},
year = {2019},
issn = {0034-5288},
doi = {https://doi.org/10.1016/j.rvsc.2019.07.002},
url = {https://www.sciencedirect.com/science/article/pii/S0034528818315686},
author = {O. {Eralp Inan} and A. Tvarijonaviciute and M. Kocaturk and C.P. Rubio and S. Kasap and M. Cansev and J.J. Ceron and Z. Yilmaz and I.H. Ulus},
keywords = {Choline, Butyrylcholinesterase, Oxidative stress, Endotoxemia, Calves},
abstract = {Endotoxemia treatment options are still of interest due to high mortality and choline treatment is one of them because of its role in the cholinergic anti-inflammatory pathway. This study investigated serum choline and butyrylcholinesterase (BChE) responses, and their correlations with inflammatory, oxidative stress and tissue damage biomarkers, including paraoxanase-1 (PON1), and clinical signs in calves with endotoxemia and the effect of choline treatment in these responses. Healthy calves (n = 20) were divided equally into 4 groups: Control (0.9% NaCl, iv), Choline (C; 1 mg/kg/iv,once), Lipopolysaccharide (LPS; 2 μg/kg/iv,once) and LPS + C. Clinical and laboratory examinations were performed before and 0.5–48 h (hrs) after treatments. Following LPS administration, serum choline level increased at 0.5-24 h (P < .01), whereas serum BChE and PON1 level decreased at 48 h (P < .01) compared to their baselines. In LPS + C group, the increase in serum choline level was significantly higher (P < .01) than that of C and LPS groups. LPS did not decrease serum BChE levels significantly in calves treated with choline. Serum choline and BChE results correlated negatively with white blood cell count and positively (P < .001) with PON1 levels, oxidative stress index, inflammation and hepato-muscular injury markers. In conclusion serum choline and BChE may have a role in the pathophysiology of endotoxemia in calves. High serum choline concentration is associated with an improvement in response to LPS administration in calves treated with choline, probably by preventing the imbalances between oxidative stress and anti-oxidant capacity, preventing the serum BChE and PON1 decreases, and inhibition/attenuation of acute phase reaction and hepato-muscular injury in calves with endotoxemia.}
}
@article{JOUBERT2020127075,
title = {Discovery of 9-phenylacridinediones as highly selective butyrylcholinesterase inhibitors through structure-based virtual screening},
journal = {Bioorganic & Medicinal Chemistry Letters},
volume = {30},
number = {9},
pages = {127075},
year = {2020},
issn = {0960-894X},
doi = {https://doi.org/10.1016/j.bmcl.2020.127075},
url = {https://www.sciencedirect.com/science/article/pii/S0960894X20301530},
author = {Jacques Joubert and Erika Kapp},
keywords = {Alzheimer’s disease, Butyrylcholinesterase inhibitors, Virtual screening, Docking, 9-Phenylacridinediones},
abstract = {Butyrylcholinesterase (BuChE) is considered a promising drug target as it plays an important role in the progression of late stage Alzheimer’s disease (AD). Two compound libraries were selected and 64 124 amine containing moieties were screened using a hierarchical virtual screening protocol to discover new selective BuChE inhibitors. From these and subsequent docking experiments, 9-phenylacridinedione (9-PAD) was identified as a promising scaffold for selective inhibition of BuChE. Selected top dock scored 9-PADs were assayed and compounds 3 and 6 exhibited potent and highly selective human BuChE inhibition (IC50: 98 nM and 142 nM, respectively). Both molecules were also predicted to show sufficient brain permeability, not have any substantial toxicities, especially hepatotoxicity, and no significant in vitro cytotoxicity against SH-SY5Y neuroblastoma cells at concentrations up to 100 µM. These findings indicate that 9-PAD is a promising lead structure for the development of agents able to treat late stage AD.}
}
@article{TAN2021110590,
title = {Molecular cloning and characterization of an atypical butyrylcholinesterase-like protein in zebrafish},
journal = {Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology},
volume = {255},
pages = {110590},
year = {2021},
issn = {1096-4959},
doi = {https://doi.org/10.1016/j.cbpb.2021.110590},
url = {https://www.sciencedirect.com/science/article/pii/S1096495921000294},
author = {Keai Sinn Tan and Yihan Zhang and Lingling Liu and Sixu Li and Xinfeng Zou and Weiping Zeng and Guohua Cheng and Dongfang Wang and Wen Tan},
keywords = {Butyrylcholinesterase, Zebrafish, Native-PAGE and LC-MS, Molecular docking, Neighbor-joining phylogenetic analysis},
abstract = {Cholinesterases act as bio scavengers to clear organophosphorus (OP) compounds and prodrugs. The butyrylcholinesterase (BChE) gene has been found in several types of teleost fish but this gene has yet to be identified in cyprinid fish. Indeed, BChE homologs have not been found in the zebrafish (Danio rerio) genomic database. Here, we demonstrate that BChE activity is present in zebrafish, in line with other groups' findings. Using in-gel native-PAGE enzymatic activity staining and LC-MS/MS technique, an atypical BChE-like protein was identified in zebrafish. The si:ch211-93f2.1 gene was cloned, and His-tagged recombinant protein was expressed using the Pichia yeast system. The purified protein (molecular weight ~ 180 kDa) showed BChE activity, and degraded acetylcholinesterase (ACh) at a higher rate than BCh. However, phylogram analysis shows that this novel cholinesterase shared an evolutionary origin with carboxylic esterase rather than BChE. The zebrafish BChE-like protein shares structural characteristics with cholinesterase and carboxylesterase. The 2-arachidonoylglycerol (2-AG), nicosulfuron, and triacetin exhibited a higher binding affinity to the zebrafish BChE-like protein than BCh and ACh. With the identification of BChE-like protein in zebrafish, this study could shed light on the origin of BChE and may contribute towards the development of a BChE knockout zebrafish model for sensitive drug or toxin screening.}
}
@article{CAI2019108756,
title = {Dimerization of human butyrylcholinesterase expressed in bacterium for development of a thermally stable bioscavenger of organophosphorus compounds},
journal = {Chemico-Biological Interactions},
volume = {310},
pages = {108756},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.108756},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719310221},
author = {Yingting Cai and Shuo Zhou and Madeline J. Stewart and Fang Zheng and Chang-Guo Zhan},
keywords = {Butyrylcholinesterase, Dimerization, Prokaryotic system, Organophosphorus, Bioscavenger},
abstract = {Human butyrylcholinesterase (BChE) is a widely distributed plasma enzyme. For decades, numerous research efforts have been directed at engineering BChE as a bioscavenger of organophosphorus insecticides and chemical warfare nerve agents. However, it has been a grand challenge to cost-efficiently produce BChE in large-scale. Recently reported studies have successfully designed a truncated BChE mutant (with amino-acid substitutions on 47 residues that are far away from the catalytic site), denoted as BChE-M47 for convenience, which can be expressed in E. coli without loss of its catalytic activity. In this study, we aimed to dimerize the truncated BChE mutant protein expressed in a prokaryotic system (E. coli) in order to further improve its thermal stability by introducing a pair of cross-subunit disulfide bonds to the BChE-M47 structure. Specifically, the E377C/A516C mutations were designed and introduced to BChE-M47, and the obtained new protein entity, denoted as BChE-M48, with a pair of cross-subunit disulfide bonds indeed exists as a dimer with significantly improved thermostability and unaltered catalytic activity and reactivity compared to BChE-M47. These results provide a new strategy for optimizing protein stability for production in a cost-efficient prokaryotic system. Our enzyme, BChE-M48, has a half-life of almost one week at a 37°C, suggesting that it could be utilized as a highly stable bioscavenger of OP insecticides and chemical warfare nerve agents.}
}
@article{ZHAO2021104656,
title = {Multivalent butyrylcholinesterase inhibitor discovered by exploiting dynamic combinatorial chemistry},
journal = {Bioorganic Chemistry},
volume = {108},
pages = {104656},
year = {2021},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2021.104656},
url = {https://www.sciencedirect.com/science/article/pii/S0045206821000328},
author = {Shuang Zhao and Jintao Xu and Shixin Zhang and Maochun Han and Yao Wu and Yusi Li and Lei Hu},
keywords = {Dynamic combinatorial chemistry, Multivalent interaction, Butyrylcholinesterase, Protein inhibition, Macromolecule},
abstract = {In this study, we report the generation of a polymer-based dynamic combinatorial library (DCL) incorporating exchangeable side chains using acylhydrazone formation reaction. In combination with tetrameric butyrylcholinesterase (BChE), the most potent binding side chain was identified, and the information obtained was further used for the synthesis of a multivalent BChE inhibitor. In the in vitro biological evaluation, this multivalent inhibitor exhibited not only better inhibitory effect than the commercial reference but also high selectivity on BChE over acetylcholinesterase (AChE).}
}
@article{MILLET2020207,
title = {Le déficit en butyrylcholinestérase plasmatique : évaluation des connaissances et de l’expérience des praticiens en anesthésie-réanimation},
journal = {Anesthésie & Réanimation},
volume = {6},
number = {2},
pages = {207-218},
year = {2020},
issn = {2352-5800},
doi = {https://doi.org/10.1016/j.anrea.2019.07.010},
url = {https://www.sciencedirect.com/science/article/pii/S2352580019301303},
author = {Clément Millet and Benoît Plaud and Hervé Delacour},
keywords = {Déficit en butyrylcholinestérase, Curarisation prolongée, Questionnaires, Anesthésistes, Connaissances, Suxamethonium, Butyrylcholinesterase deficiency, Prolonged curarisation, Surveys, Anaesthetists, Knowledge, Suxamethonium},
abstract = {Résumé
L’utilisation du suxaméthonium peut être associée à deux grands risques : un risque immuno-allergique et un risque de curarisation prolongée en cas de déficit en butyrylcholinestérase (BChE). Les modalités diagnostiques ainsi que l’exploration d’un déficit en BChE ne semblent pas toujours maîtrisées par les praticiens. Notre étude avait pour objectif principal de réaliser un état des lieux des connaissances des anesthésistes-réanimateurs sur cette thématique. Un questionnaire informatisé anonyme a été adressé aux membres de la SFAR. Les questions couvraient tous les aspects du déficit en butyrylcholinestérase (étiologies, prévalence, modalités de transmission, critères de suspicion clinique et modalités de prise en charge immédiate et à long terme). Un score sur soixante-dix évaluait le niveau de connaissance. Cinq cent soixante-dix-huit anesthésistes-réanimateurs, soit environ 22 % des membres de la SFAR ont participé à l’étude. Le score médian observé est de 31 points sur 70. Les questions de connaissances théoriques ont un score médian faible (de 0 à 3/10). À l’inverse, les questions sur les modalités de prise en charge sont associées à un score médian élevé (10/10). Les praticiens ayant déjà été confronté à un déficit en BChE ont un score plus important que ceux n’y ayant jamais été confronté (34 vs 30, p<0,05). Le niveau de connaissance des anesthésistes sur la thématique du déficit en BChE semble faible et est certainement à l’origine d’une sous-estimation potentielle du nombre de cas de curarisation prolongée. La création d’une fiche réflexe pourrait permettre d’améliorer la prise en charge des patients présentant un tel déficit.
Summary
The use of suxamethonium can be associated with two major complications: an immuno-allergic risk and a risk of prolonged apnoea in case of butyrylcholinesterase deficiency (BChE). The diagnosis and clinical management of BChE deficiency seem to be not always mastered by the anaesthetists. In this context, the aim of our study was to perform an evaluation of the French anaesthetists’ knowledge in this topic. An online questionnaire was distributed to SFAR members. The questions covered all the aspects of BChE deficiency (etiologies, prevalence, inheritance pattern, clinical suspicion criteria, and immediate and long-term management). The knowledge of each participant was assessed using a 70-point scoring system. Five hundred and seventy-eight anaesthetists (nearly 22% of SFAR members) participated in the study. A median score of 31 points is observed. The questions evaluating the theoretical aspects of BChE deficiency (etiologies, prevalence, and inheritance pattern) are associated with a lower median score (from 0 to 3/10) than those evaluating the clinical management of BChE deficient patients (clinical suspicion criteria, and immediate and long-term management) (10/10). Practitioners who have previously treated a BChE deficient patient have a higher score than those who have never been confronted to such a situation (34 vs. 30, P<0.05). The level of knowledge of the French anaesthetists on the topic of BChE deficiency is perfectible, particularly concerning its theoretical aspects. It can induce a potential underestimation of the real burden of prolonged apnoea and a non-optimal management of the patients. The creation and diffusion of a reflex card are desirable to improve the management of BChE deficient patients.}
}
@article{XING20211352,
title = {Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening},
journal = {International Journal of Biological Macromolecules},
volume = {166},
pages = {1352-1364},
year = {2021},
issn = {0141-8130},
doi = {https://doi.org/10.1016/j.ijbiomac.2020.11.015},
url = {https://www.sciencedirect.com/science/article/pii/S0141813020349394},
author = {Shuaishuai Xing and Ying Chen and Baichen Xiong and Weixuan Lu and Qi Li and Yuanyuan Wang and Mengxia Jiao and Feng Feng and Yao Chen and Wenyuan Liu and Haopeng Sun},
keywords = {Virtual screening, Selective butyrylcholinesterase inhibitor, Alzheimer's disease},
abstract = {In recent years, butyrylcholinesterase (BChE) has gradually gained worldwide interests as a novel target for treating Alzheimer's disease (AD). Here, two pharmacophore models were generated using Schrödinger suite and used to virtually screen ChemDiv database, from which three hits were obtained. Among them, 2513–4169 displayed the highest inhibitory activity and selectivity against BChE (eeAChE IC50 > 10 μM, eqBChE IC50 = 3.73 ± 1.90 μM). Molecular dynamic (MD) simulation validated the binding pattern of 2513–4169 in BChE, and it could form a various of receptor-ligand interactions with adjacent residues. In vitro cytotoxicity assay proved the safety of 2513–4169 on diverse neural cell lines. Moreover, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay performed on SH-SY5Y cells proved the neuroprotective effect of 2513–4169 against toxic Aβ1–42. In vivo behavioral study further confirmed the great efficacy of 2513–4169 on reversing Aβ1–42-induced cognitive impairment of mice and clearing the toxic Aβ1–42 in brains. Moreover, 2513–4169 was proved to be able to cross blood-brain barrier (BBB) through a parallel artificial membrane permeation assay of BBB (PAMPA-BBB). Taken together, 2513–4169 is a promising lead compound for future optimization to discover anti-AD treating agents.}
}
@article{DUBROVSKII2019374,
title = {Mass spectrometry based proteomic approach for the screening of butyrylcholinesterase adduct formation with organophosphates},
journal = {Talanta},
volume = {197},
pages = {374-382},
year = {2019},
issn = {0039-9140},
doi = {https://doi.org/10.1016/j.talanta.2019.01.059},
url = {https://www.sciencedirect.com/science/article/pii/S0039914019300591},
author = {Yaroslav Dubrovskii and Ekaterina Murashko and Olga Chuprina and Petr Beltyukov and Andrey Radilov and Nikolay Solovyev and Vladimir Babakov},
keywords = {Immunomagnetic separation, Covalent inhibition, Adducts, Cholinesterase, Organophosphorus compound, Target proteomics},
abstract = {Organophosphates’ toxic effect causes covalent binding to serine-198 in the active site of human plasma butyrylcholinesterase (BChE) with loss of enzymatic function (covalent inhibition). Mass spectrometric detection of modified FGESAGAAS peptide at the active site is a powerful exposure biomarker tool. The aim of this study was to develop mass spectrometry-based method for BChE adduct formation screening, avoiding the use of standard peptides. Immunomagnetic separation of proteins from plasma was optimized. Commercially available anti-butyrylcholinesterase monoclonal antibodies, immobilized on magnetic beads, resulted in stable and reusable affinity sorbent. The method was tested on horse serum BChE and real human plasma from healthy donors, treated with Russian VX (VR). The BChE isolated from blood plasma was digested with pepsin and analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). The method was evaluated by using synthetic peptides and by comparison to the enzymatic activity Ellman's assay. The minimum concentration of VR exposure, resulting in detectable VR-adduct, was 0.2 ng/mL, which corresponded to the relative BChE inhibition of less than 2%. Adduct formation assessment was performed via monitoring of decrease in non-modified peptide LC-MS/MS signal and increase in VR-modified peptide signal. The designed approach was tested in a pilot study with 5 blood samples from healthy volunteers. Mass spectrometry-based method for BChE adduct formation was found to be in agreement with Ellman's inhibition assay, so the method is applicable for direct BChE inhibition assessment.}
}
@article{NECHAEVA201875,
title = {Quantitative butyrylcholinesterase activity detection by surface-enhanced Raman spectroscopy},
journal = {Sensors and Actuators B: Chemical},
volume = {259},
pages = {75-82},
year = {2018},
issn = {0925-4005},
doi = {https://doi.org/10.1016/j.snb.2017.11.174},
url = {https://www.sciencedirect.com/science/article/pii/S0925400517323055},
author = {Natalia Nechaeva and Taisiya Prokopkina and Galina Makhaeva and Elena Rudakova and Natalia Boltneva and Christophor Dishovsky and Arkadiy Eremenko and Ilya Kurochkin},
keywords = {Butyrylcholinesterase, Thiocholine, Butyrylthiocholine, Raman spectroscopy, Silver SERS-substrate, PLS regression},
abstract = {The butyrylcholinesterase activity in human blood is an important marker of healthiness. Either level of this enzyme – increased or otherwise – can indicate disease or intoxication. The most popular technique to assess the cholinesterase activity is the detection of thiocholine, a product of enzymatic hydrolysis of butyrylthiocholine. In this work, Ag-paste was used as SERS-substrate and a new technique was created for thiocholine detection. As explained below, the designed technique facilitates also determination of butyrylcholinesterase (BChE) activity both in the buffer and in spike solution with human plasma. Ellman’s assay was used as a reference method, a good correlation between spectrophotometric detection and Raman detection was shown.}
}
@article{ZORBAZ201916,
title = {Butyrylcholinesterase inhibited by nerve agents is efficiently reactivated with chlorinated pyridinium oximes},
journal = {Chemico-Biological Interactions},
volume = {307},
pages = {16-20},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.04.020},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719303941},
author = {Tamara Zorbaz and David Malinak and Kamil Kuca and Kamil Musilek and Zrinka Kovarik},
keywords = {Organophosphorus compounds, Quaternary oxime, Reactivators, Cholinesterase, Pseudo-catalytic scavenger},
abstract = {Bispyridinium oximes with one (K865, K866, K867) or two (K868, K869, K870) ortho-positioned chlorine moiety, analogous to previously known K027, K048 and K203 oximes, and potent reactivators of human acetylcholinesterase (AChE) inhibited by nerve agents, were tested in the reactivation of human butyrylcholinesterase (BChE) inhibited by sarin, cyclosarin, VX, and tabun. A previously highlighted AChE reactivator, dichlorinated bispyridinium oxime with propyl linker (K868), was tested in more detail for reactivation of four nerve agent-BChE conjugates. Its BChE reactivation potency was showed to be promising when compared to the standard oximes used in medical practice, asoxime (HI-6) and pralidoxime (2-PAM), especially in case of sarin and tabun. This finding could be used in the pseudo-catalytic scavenging of the most nerve agents due to its cumulative capacity to reactivate both AChE and BChE.}
}
@article{ZHOU2019372,
title = {Structure-based virtual screening leading to discovery of highly selective butyrylcholinesterase inhibitors with solanaceous alkaloid scaffolds},
journal = {Chemico-Biological Interactions},
volume = {308},
pages = {372-376},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.05.051},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719303540},
author = {Shuo Zhou and Yaxia Yuan and Fang Zheng and Chang-Guo Zhan},
abstract = {According to recent research advance, it is interesting to identify new, potent and selective inhibitors of human butyrylcholinesterase (BChE) for therapeutic treatment of both the Alzheimer's disease (AD) and heroin abuse. In this study, we carried out a structure-based virtual screening followed by in vitro activity assays, with the goal to identify new inhibitors that are selective for BChE over acetylcholinesterase (AChE). As a result, a set of new, selective inhibitors of human BChE were identified from natural products with solanaceous alkaloid scaffolds. The most active one of the natural products (compound 1) identified has an IC50 of 16.8 nM against BChE. It has been demonstrated that the desirable selectivity of these inhibitors for BChE over AChE is mainly controlled by three key residues in the active site cavity, i.e. residues Q119, A277, and A328 in BChE versus the respective residues Y124, W286, and Y337 in AChE. Based on this structural insight, future rational design of new, potent and selective BChE inhibitors may focus on these key structural differences in the active site cavity.}
}
@article{ALKANAIMSH201958,
title = {Purification and site-specific N-glycosylation analysis of human recombinant butyrylcholinesterase from Nicotiana benthamiana},
journal = {Biochemical Engineering Journal},
volume = {142},
pages = {58-67},
year = {2019},
issn = {1369-703X},
doi = {https://doi.org/10.1016/j.bej.2018.11.004},
url = {https://www.sciencedirect.com/science/article/pii/S1369703X1830398X},
author = {Salem Alkanaimsh and Jasmine M. Corbin and Muchena J. Kailemia and Kalimuthu Karuppanan and Raymond L. Rodriguez and Carlito B. Lebrilla and Karen A. McDonald and Somen Nandi},
keywords = {butyrylcholinesterase, , downstream processing, Hupresin, Biopharmaceutical},
abstract = {Butyrylcholinesterase (BChE) is a glycosylated serine hydrolase found in human serum that has been shown to protect against various cholinesterase-inhibiting organophosphate nerve agents. The supply of plasma-derived butyrylcholinesterase (hBChE) is constrained by the availability of human blood and a complex purification process and its high cost. This constraints necessitates the development of expression platforms capable of large-scale, low-cost production of an active recombinant BChE (rBChE). Traditionally, procainamide affinity chromatography has been used to purify BChE. Recently, an effective affinity chromatography resin based on a potent cholinesterase inhibitor (tacrine-huperzine A hybrid; huperine X termed as Hupresin®) was developed. Here, we describe a purification scheme of rBChE from Nicotiana benthamiana plants. Different extraction buffers were screened for their ability to extract rBChE and native plant proteins. Citrate buffer at pH 4 was selected to minimize extraction of host plant proteins and showed a 4.5-fold enhancement in rBChE specific activity compared to Tris buffer, pH 8. DEAE-Sepharose chromatography increased the purity of rBChE by 70% by removing major host plant protein impurities. The rBChE was then adsorbed to Hupresin® and purified to homogeneity for an overall process yield of 34%. The purification process represents a threefold higher product yield over the established process. Mass spectrometry confirmed the protein sequence and site-specific N-glycosylation analysis was performed.}
}
@article{VILELA201853,
title = {An improved immobilized enzyme reactor-mass spectrometry-based label free assay for butyrylcholinesterase ligand screening},
journal = {Analytical Biochemistry},
volume = {549},
pages = {53-57},
year = {2018},
issn = {0003-2697},
doi = {https://doi.org/10.1016/j.ab.2018.03.012},
url = {https://www.sciencedirect.com/science/article/pii/S0003269718302689},
author = {Adriana Ferreira Lopes Vilela and Cláudia Seidl and Juliana Maria Lima and Carmen Lúcia Cardoso},
abstract = {Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are key cholinesterase enzymes responsible for the hydrolysis of acetylcholine into choline and acetic acid, an essential process for the restoration of the cholinergic neuron. The loss of cholinergic function in the central nervous system contributes to the cognitive decline associated with advanced age and Alzheimer's disease (AD). Inhibitions assays represent a significant role in the drug discovery process. Herein, we describe an improved label free method to screen and characterize new BChE ligands. The liquid chromatography system uses an immobilized capillary enzyme reactor (ICER) as a low affinity and high selectivity column coupled to a mass spectrometer (MS). The enzyme activity was evaluated by monitoring the choline's precursor ion [M + H]+ m/z 104 for a brief period. The method was validated using two known cholinesterase inhibitors tacrine and galanthamine. The IC50 values were 0.03 ± 0.006 μM and 0.88 ± 0.2 for tacrine and galanthamine respectively, and Ki was 0.11 ± 0.2 for galanthamine. The efficient combination of the huBChE-ICER with sensitive enzymatic assay detection such as MS, improved the reliable, fast identification of new ligands. Moreover, specific direct quantitation of the product contributes to the reduction of false positive and negative results.}
}
@article{WU2019102949,
title = {Highly selective carbamate-based butyrylcholinesterase inhibitors derived from a naturally occurring pyranoisoflavone},
journal = {Bioorganic Chemistry},
volume = {88},
pages = {102949},
year = {2019},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2019.102949},
url = {https://www.sciencedirect.com/science/article/pii/S0045206819301610},
author = {Chuanhai Wu and Yan-bei Tu and Ziyuan Li and Yan-fang Li},
keywords = {Butyrylcholinesterase inhibitor, Pyranoisoflavone, Carbamates, Kinetic study, Molecular docking},
abstract = {This current study described the design and synthesis of a series of derivatives based on a natural pyranoisaflavone, which was obtained from the seeds of Millettia pachycarpa and displayed attractive BChE inhibition and high selectivity in our previous study. The inhibitory potential of all derivatives against two cholinesterases was evaluated. Only a few compounds demonstrated AChE inhibitory activity at the tested concentrations, while 26 compounds showed significant inhibition on BChE (the IC50 values varied from 9.34 μM to 0.093 μM), most of them presented promising selectivity to ward BChE. Prediction of ADME properties for 7 most active compounds was performed. Among them, 9g (IC50 = 222 nM) and 9h (IC50 = 93 nM) were found to be the most potent BChE inhibitors with excellent selectivity over AChE (SI ratio = 1339 and 836, respectively). The kinetic analysis demonstrated both of them acted as mixed-type BChE inhibitors, while the molecular docking results indicated that they interacted with both residues in the catalytic active site. A cytotoxicity test on PC12 cells showed that both 9g and 9h had a therapeutic safety range similar to tacrine. Overall, the results indicate that 9h could be a good candidate of BChE inhibitors.}
}
@article{SAXENA201838,
title = {Characterization of butyrylcholinesterase from porcine milk},
journal = {Archives of Biochemistry and Biophysics},
volume = {652},
pages = {38-49},
year = {2018},
issn = {0003-9861},
doi = {https://doi.org/10.1016/j.abb.2018.06.006},
url = {https://www.sciencedirect.com/science/article/pii/S0003986118302534},
author = {Ashima Saxena and Tatyana Belinskaya and Lawrence M. Schopfer and Oksana Lockridge},
keywords = {Butyrylcholinesterase, Acetylcholinesterase, Porcine, Polyproline, Tetramer, Hupresin},
abstract = {Human butyrylcholinesterase (HuBChE) is under development for use as a pretreatment antidote against nerve agent toxicity. Animals are used to evaluate the efficacy of HuBChE for protection against organophosphorus nerve agents. Pharmacokinetic studies of HuBChE in minipigs showed a mean residence time of 267 h, similar to the half-life of HuBChE in humans, suggesting a high degree of similarity between BChE from 2 sources. Our aim was to compare the biochemical properties of PoBChE purified from porcine milk to HuBChE purified from human plasma. PoBChE hydrolyzed acetylthiocholine slightly faster than butyrylthiocholine, but was sensitive to BChE-specific inhibitors. PoBChE was 50-fold less sensitive to inhibition by DFP than HuBChE and 5-fold slower to reactivate in the presence of 2-PAM. The amino acid sequence of PoBChE determined by liquid chromatography tandem mass spectrometry was 91% identical to HuBChE. Monoclonal antibodies 11D8, mAb2, and 3E8 (HAH 002) recognized both PoBChE and HuBChE. Assembly of 4 identical subunits into tetramers occurred by noncovalent interaction with polyproline-rich peptides in PoBChE as well as in HuBChE, though the set of polyproline-rich peptides in milk-derived PoBChE was different from the set in plasma-derived HuBChE tetramers. It was concluded that the esterase isolated from porcine milk is PoBChE.}
}
@article{ZEMAN201926,
title = {Tubes for detection of cholinesterase inhibitors—Unique effects of Neusilin on the stability of butyrylcholinesterase-impregnated carriers},
journal = {Enzyme and Microbial Technology},
volume = {128},
pages = {26-33},
year = {2019},
issn = {0141-0229},
doi = {https://doi.org/10.1016/j.enzmictec.2019.05.002},
url = {https://www.sciencedirect.com/science/article/pii/S0141022919300699},
author = {Jiří Zeman and David Vetchý and Sylvie Pavloková and Aleš Franc and Vladimír Pitschmann and Martin Dominik and Martina Urbanová and Ivana Šeděnková},
keywords = {Cholinesterase, Detection, Enzyme, Nerve agent, Neusilin, Stability},
abstract = {Detection tubes are small devices for the colorimetric enzymatic detection of cholinesterase inhibitors such as sarin, soman, VX nerve agents and substances denoted as Novichok. These detectors contain carriers in the form of pellets with immobilized cholinesterase, substrate and detection reagent. Their advantages are portability, sensitivity and simplicity, enabling fast detection of such compounds from air and water in case of a terrorist attack or war. In general, maintaining the stability of an enzyme for a longer time is very problematic; therefore, its further enhancement is required for safety and financial reasons. In this study, the stability of our patented carriers in the form of pellets with immobilized butyrylcholinesterase containing an increasing amount of the unique sorbent Neusilin® US2 was evaluated. The samples containing Neusilin maintained the stability of the immobilized enzyme for a longer time even at higher temperature and humidity than the currently commercially used carrier without Neusilin, allowing improved detection of nerve agents.}
}
@article{RAHIM201630,
title = {Synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory potential of hydrazide based Schiff bases},
journal = {Bioorganic Chemistry},
volume = {68},
pages = {30-40},
year = {2016},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2016.07.005},
url = {https://www.sciencedirect.com/science/article/pii/S0045206816301122},
author = {Fazal Rahim and Hayat Ullah and Muhammad Taha and Abdul Wadood and Muhammad Tariq Javed and Wajid Rehman and Mohsan Nawaz and Muhammad Ashraf and Muhammad Ali and Muhammad Sajid and Farman Ali and Muhammad Naseem Khan and Khalid Mohammed Khan},
keywords = {Synthesis, Acetylcholinesterase, Butyrylcholinesterase, Molecular docking, Schiff bases, SAR},
abstract = {To discover multifunctional agents for the treatment of Alzheimer’s disease, a series of hydrazide based Schiff bases were designed and synthesized based on multitarget-directed strategy. We have synthesized twenty-eight analogs of hydrazide based Schiff bases, characterized by various spectroscopic techniques and evaluated in vitro for acetylcholinesterase and butyrylcholinesterase inhibition. All compounds showed varied degree of acetylcholinesterase and butyrylcholinesterase inhibition when compared with standard Eserine. Among the series, compounds 10, 3 and 24 having IC50 values 4.12±0.01, 8.12±0.01 and 8.41±0.06μM respectively showed potent acetylcholinesterase inhibition when compared with Eserine (IC50=0.85±0.0001μM). Three compounds 13, 24 and 3 having IC50 values 6.51±0.01, 9.22±0.07 and 37.82±0.14μM respectively showed potent butyrylcholinesterase inhibition by comparing with eserine (IC50=0.04±0.0001μM). The remaining compounds also exhibited moderate to weak inhibitory potential. Structure activity relationship has been established. Through molecular docking studies the binding interaction was confirmed.}
}
@article{CERBAI2007142,
title = {N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: A comparison with donepezil and rivastigmine},
journal = {European Journal of Pharmacology},
volume = {572},
number = {2},
pages = {142-150},
year = {2007},
issn = {0014-2999},
doi = {https://doi.org/10.1016/j.ejphar.2007.06.053},
url = {https://www.sciencedirect.com/science/article/pii/S0014299907007716},
author = {Francesca Cerbai and Maria Grazia Giovannini and Claudia Melani and Albert Enz and Giancarlo Pepeu},
keywords = {Acetylcholine, Acetylcholinesterase, Butyrylcholinesterase, Cholinesterase inhibitors, Microdialysis},
abstract = {The effects of (−)-N1phenethyl-norcymserine (PEC, 5 mk/kg, i.p.) on acetylcholine release and cholinesterase activity in the rat cerebral cortex were compared with those of donepezil (1 mg/kg, i.p.), a selective acetylcholinesterase inhibitor, and rivastigmine (0.6 mg/kg, i.p.), an inhibitor of acetylcholinesterase and butyrylcholinesterase. Acetylcholine extracellular levels were measured by microdialysis coupled with HPLC; acetylcholinesterase and butyrylcholinesterase activity were measured with colorimetric and radiometric methods. It was found that comparable 2–3 fold increases in cortical extracellular acetylcholine level, calculated as areas under the curve, followed the administration of the three drugs at the doses used. At the peak of acetylcholine increase, a 27% acetylcholinesterase inhibition and no butyrylcholinesterase inhibition was found after donepezil (1 mg/kg, i.p) administration. At the same time point, rivastigmine (0.6 mg/kg, i.p.) inhibited acetylcholinesterase by 40% and butyrylcholinesterase by 25%. After PEC (5 mg/kg, i.p.) administration, there was a 39% butyrylcholinesterase inhibition and no effect on acetylcholinesterase. Since in the present study it was also confirmed that in the brain butyrylcholinesterase activity is only about 10% of acetylcholinesterase activity, it is surprising that its partial inhibition is sufficient to increase extracellular acetylcholine levels. The importance of butyrylcholinesterase as a “co-regulator” of synaptic acetylcholine levels should thus be reconsidered.}
}
@article{QU2021121831,
title = {Determination of butyrylcholinesterase activity based on thiamine luminescence modulated by MnO2 nanosheets},
journal = {Talanta},
volume = {224},
pages = {121831},
year = {2021},
issn = {0039-9140},
doi = {https://doi.org/10.1016/j.talanta.2020.121831},
url = {https://www.sciencedirect.com/science/article/pii/S003991402031122X},
author = {Zhengyi Qu and Tian Yu and Yuzhong Liu and Lihua Bi},
keywords = {Enzymatic assay, Non-fluorescent substrate, Butyrylcholinesterase, Fluorescence change},
abstract = {In this paper, a novel strategy for biosensing butyrylcholinesterase (BChE) activity is developed based on manganese dioxide (MnO2) nanosheets to modulate the photoluminescence of thiamine (TH). The oxidase-like activity of MnO2 nanosheets enables them to catalyze the oxidation of non-fluorescent substrate TH to generate strong fluorescent thiochrome (TC). When the target BChE is introduced to form thiocholine in the presence of S-butyrylthiocholine iodide (BTCh), MnO2 nanosheets are reduced by thiocholine to Mn2+, resulting in the loss of their oxidase-like activity and the reduction of TC fluorescence. Based on this, a BChE activity fluorescence biosensor is constructed utilizing the luminescence behavior variation of TH and the oxidase-like activity of MnO2 nanosheets. The fluorescence biosensor shows a sensitive response to BChE, and the detection limit reaches 0.036 U L−1. In addition, the feasibility of the biosensor in real samples analysis is studied with satisfactory results.}
}
@article{BEGUM2018212,
title = {In-vitro evaluation and in-silico studies applied on newly synthesized amide derivatives of N-phthaloylglycine as Butyrylcholinesterase (BChE) inhibitors},
journal = {Computational Biology and Chemistry},
volume = {74},
pages = {212-217},
year = {2018},
issn = {1476-9271},
doi = {https://doi.org/10.1016/j.compbiolchem.2018.04.003},
url = {https://www.sciencedirect.com/science/article/pii/S147692711730049X},
author = {Samreen Begum and Shaikh Sirajuddin Nizami and Uzma Mahmood and Summyia Masood and Sahar Iftikhar and Summayya Saied},
keywords = {Amide, Butyrylcholinesterase (BChE), Alzheimer’s disease, Computer aided drug designing (CADD), Molecular docking simulation,  studies, Schotten Baumann reaction},
abstract = {Amide derivatives of N-phthaloylglycine were synthesized under Schotten Baumann reaction condition. The structures of synthesized compounds (4a–d) were characterized by using FTIR, 1HNMR and EI-MS. The compounds were evaluated for their in-vitro Butyrylcholinesterase inhibition and all of them exhibited good activity against this enzyme. Compound 4a (IC50 = 6.5 ± 0.1) was found to be most potent compared with the reference compound Galantamine (IC50 = 6.6 ± 0.00038) and the other compounds (4b,4c,4d) were also possess that activity and hence can be employed for the discovery of lead compounds against Alzheimer’s disease. The depth analysis of the binding mechanism of these newly synthesized compounds inside the binding gorge of BChE, an in silico technique, molecular docking was performed. All the compounds were found to be well accommodated within the binding pocket of BChE. Compounds 4a, 4b and 4c showed hydrogen bonding interaction with binding site residue TYR332. Moreover, hydrophobic and π–π interaction assisted the compounds to attain their enzyme inhibitory activity. These theoretical studies showed significant correlation with experimental results.}
}
@article{DEALMEIDA2019113,
title = {Surface screening, molecular modeling and in vitro studies on the interactions of aflatoxin M1 and human enzymes acetyl- and butyrylcholinesterase},
journal = {Chemico-Biological Interactions},
volume = {308},
pages = {113-119},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.05.022},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719303357},
author = {Joyce S.F.D. {de Almeida} and Samir F.de A. Cavalcante and Rafael Dolezal and Kamil Kuca and Kamil Musilek and Daniel Jun and Tanos C.C. França},
keywords = {Aflatoxin M1, Surface screening, Molecular modeling, Acetylcholinesterase, Butyrylcholinesterase},
abstract = {Aflatoxin M1 (AFM1) is a mycotoxin produced by Aspergillus fungi and found in contaminated milk, breastfeed and dairy products, being highly toxic and carcinogenic to humans and other mammalian species. It is also produced in the human body as a metabolite of aflatoxin B1 (AFB1), one of the most toxic natural products known. Previous studies have shown that AFM1 is a potential inhibitor of the enzyme acetylcholinesterase (AChE), and therefore, a potential neurotoxic agent. In this work, surface screening (SS) and molecular dynamics (MD) simulation on human acetylcholinesterase AChE (HssAChE) were performed to corroborate literature data regarding preferential binding sites and type of inhibition. Also, an inedited theoretical study on the interactions of AFM1 with human butyrylcholinesterase (HssBChE) was performed. In vitro inhibition tests on both enzymes were done to support theoretical results. MD simulations suggested the catalytic anionic site of HssAChE as the preferential binding site for AFM1 and also that this metabolite is not a good inhibitor of HssBChE, corroborating previous studies. In vitro assays also corroborated molecular modeling studies by showing that AFM1 did not inhibit BChE and was able to inhibit AChE, although not as much as AFB1.}
}
@article{MEDEN2020112766,
title = {Structure-activity relationship study of tryptophan-based butyrylcholinesterase inhibitors},
journal = {European Journal of Medicinal Chemistry},
volume = {208},
pages = {112766},
year = {2020},
issn = {0223-5234},
doi = {https://doi.org/10.1016/j.ejmech.2020.112766},
url = {https://www.sciencedirect.com/science/article/pii/S0223523420307388},
author = {Anže Meden and Damijan Knez and Natalia Malikowska-Racia and Xavier Brazzolotto and Florian Nachon and Jurij Svete and Kinga Sałat and Uroš Grošelj and Stanislav Gobec},
keywords = {Cholinesterase inhibitors, Alzheimer’s disease, Butyrylcholinesterase, Neurodegenerative diseases},
abstract = {A series of tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors was designed and synthesized. Compounds were optimized in terms of potency, selectivity, and synthetic accessibility. The crystal structure of the inhibitor 18 in complex with BChE revealed the molecular basis for its low nanomolar inhibition (IC50 = 2.8 nM). The favourable in vitro results enabled a first-in-animal in vivo efficacy and safety trial, which demonstrated a positive impact on fear-motivated and spatial long-term memory retrieval without any concomitant adverse motor effects. Altogether, this research culminated in a handful of new lead compounds with promising potential for symptomatic treatment of patients with Alzheimer’s disease.}
}
@article{GULCIN2020104171,
title = {Synthesis of nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds – Determination of their carbonic anhydrase, acetylcholinesterase, butyrylcholinesterase and α-glycosidase inhibition properties},
journal = {Bioorganic Chemistry},
volume = {103},
pages = {104171},
year = {2020},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2020.104171},
url = {https://www.sciencedirect.com/science/article/pii/S0045206820314681},
author = {İlhami Gülçin and Boris Trofimov and Ruya Kaya and Parham Taslimi and Lyubov Sobenina and Elena Schmidt and Olga Petrova and Svetlana Malysheva and Nina Gusarova and Vagif Farzaliyev and Afsun Sujayev and Saleh Alwasel and Claudiu T. Supuran},
keywords = {Pyrrole, Carbonic anhydrase, Enzyme inhibition, α-Glycosidase, Acetylcholinesterase, Butyrylcholinesterase},
abstract = {Sulfur-containing pyrroles (1–3), tris(2-pyridyl)phosphine(selenide) sulfide (4–5) and 4-benzyl-6-(thiophen-2-yl)pyrimidin-2-amine (6) were synthesized and characterized by elemental analysis, IR and NMR spectra. In this study, the synthesized compounds of nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds (1–6) were evaluated against the human erythrocyte carbonic anhydrase I, and II isoenzymes, acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α-glycosidase enzymes. The synthesized heterocyclic compounds showed IC50 values in range of 33.32–60.79 nM against hCA I, and 37.05–66.64 nM against hCA II closely associated with various physiological and pathological processes. On the other hand, IC50 values were found in range of 13.13–22.21 nM against AChE, 0.54–31.22 nM against BChE, and 13.51–26.55 nM against α-glycosidase as a hydrolytic enzyme. As a result, nitrogen, phosphorus, selenium and sulfur-containing heterocyclic compounds (1–6) demonstrated potent inhibition profiles against indicated metabolic enzymes. Therefore, we believe that these results may contribute to the development of new drugs particularly in the treatment of some global disorders including glaucoma, Alzheimer’s disease and diabetes.}
}
@article{LIN2019S185,
title = {Knockdown of butyrylcholinesterase in the hippocampal ca1 strengthen contextual fear memory},
journal = {IBRO Reports},
volume = {6},
pages = {S185-S186},
year = {2019},
note = {IBRO World Congress},
issn = {2451-8301},
doi = {https://doi.org/10.1016/j.ibror.2019.07.581},
url = {https://www.sciencedirect.com/science/article/pii/S2451830119306338},
author = {Zhengdong Lin and Si Chen and Kai-Leng Tan and Wen Tan}
}
@article{TOUBLET2021113059,
title = {Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT6 receptor antagonist with therapeutic interest in Alzheimer’s disease},
journal = {European Journal of Medicinal Chemistry},
volume = {210},
pages = {113059},
year = {2021},
issn = {0223-5234},
doi = {https://doi.org/10.1016/j.ejmech.2020.113059},
url = {https://www.sciencedirect.com/science/article/pii/S022352342031031X},
author = {François-Xavier Toublet and Julien Lalut and Bérénice Hatat and Cédric Lecoutey and Audrey Davis and Marc Since and Sophie Corvaisier and Thomas Freret and Jana {Sopková-de Oliveira Santos} and Sylvie Claeysen and Michel Boulouard and Patrick Dallemagne and Christophe Rochais},
keywords = {Alzheimer’s disease, Prodrugs, Butyrylcholinesterase, 5-HT receptors, MTDL},
abstract = {Beside acetylcholinesterase, butyrylcholinesterase could be considered as a putative target of interest for the symptomatic treatment of Alzheimer’s disease (AD). As a result of complexity of AD, no molecule has been approved since 2002. Idalopirdine, a 5-HT6 receptors antagonist, did not show its effectiveness in clinical trial despite its evaluation as adjunct to cholinesterase inhibitors. Pleiotropic molecules, known as multitarget directed ligands (MTDLs) are currently developed to tackle the multifactorial origin of AD. In this context, we have developed a pleiotropic carbamate 7, that behaves as a covalent inhibitor of BuChE (IC50 = 0.97 μM). The latter will deliver after hydrolysis, compound 6, a potent 5-HT6 receptors antagonist (Ki = 11.4 nM) related to idalopirdine. In silico and in vitro evaluation proving our concept were performed completed with first in vivo results that demonstrate great promise in restoring working memory.}
}
@article{CERASOLI2020113670,
title = {Butyrylcholinesterase, a stereospecific in vivo bioscavenger against nerve agent intoxication},
journal = {Biochemical Pharmacology},
volume = {171},
pages = {113670},
year = {2020},
issn = {0006-2952},
doi = {https://doi.org/10.1016/j.bcp.2019.113670},
url = {https://www.sciencedirect.com/science/article/pii/S0006295219303697},
author = {Douglas M. Cerasoli and Stuart J. Armstrong and Tony E. Reeves and Sean M. Hodgins and Shane A. Kasten and Robyn B. Lee-Stubbs and C. Linn Cadieux and Tamara C. Otto and Benedict R. Capacio and David E. Lenz},
keywords = {Butyrylcholinesterase, Stoichiometry, Bioscavenger, Nerve agent, Prophylaxis},
abstract = {Human butyrylcholinesterase (E.C. 3.1.1.8) purified from blood plasma has previously been shown to provide protection against up to five and a half times the median lethal dose of an organophosphorus nerve agent in several animal models. In this study the stoichiometric nature of the protection afforded by human butyrylcholinesterase against organophosphorus nerve agents was investigated in guinea pigs. Animals were administered human butyrylcholinesterase (26.15 mg/kg ≡ 308 nmol/kg) by the intravascular or intramuscular route. Animals were subsequently dosed with either soman or VX in accordance with a stage-wise adaptive dose design to estimate the modified median lethal dose in treated animals. Human butyrylcholinesterase (308 nmol/kg) increased the median lethal dose of soman from 154 nmol/kg to 770 nmol/kg. Comparing the molar ratio of agent molecules to enzyme active sites yielded a stoichiometric protective ratio of 2:1 for soman, likely related to the similar stereoselectivity the enzyme has compared to the toxic target, acetylcholinesterase. In contrast, human butyrylcholinesterase (308 nmol/kg) increased the median lethal dose of VX from 30 nmol/kg to 312 nmol/kg, resulting in a stoichiometric protective ratio of only 1:1, suggesting a lack of stereoselectivity for this agent.}
}
@article{MACKLIN2020127213,
title = {Synthesis, biochemical evaluation, and molecular modeling of organophosphate-coumarin hybrids as potent and selective butyrylcholinesterase inhibitors},
journal = {Bioorganic & Medicinal Chemistry Letters},
volume = {30},
number = {13},
pages = {127213},
year = {2020},
issn = {0960-894X},
doi = {https://doi.org/10.1016/j.bmcl.2020.127213},
url = {https://www.sciencedirect.com/science/article/pii/S0960894X20303139},
author = {Lee J. Macklin and Jason P. Schwans},
keywords = {Butyrylcholinesterase, Coumarin, SwissDock, Alzheimer's Disease, Warfarin},
abstract = {A small library of new organophosphorylated warfarins and 3-benzylcoumarins were synthesized and evaluated for in vitro cholinesterase inhibition by Ellman’s method. Most of the compounds were found to be selective for butyrylcholinesterase (BChE) over acetylcholinesterase (AChE), with IC50 values ranging from 0.363 μM to 53.0 μM determined after 15 s of enzyme exposure. Comparison of the most potent compound, 3b with its constitutional isomer 2b revealed the high importance of phosphate positioning. Reversed selectivity and a 100-fold reduction in anti-BChE activity was observed when the organophosphate was attached to the benzyl instead of the coumarin. Docking calculations suggest that 3b binds initially as a transition state mimic with near-optimal phosphate orientation relative to S198 and occupation of the oxyanion hole prior to phosphorylation. These results might inspire the design of a new type of non-neuropathic and irreversible coumarin-based inhibitor against BChE.}
}
@article{EDZIRI201884,
title = {Phytochemical screening, butyrylcholinesterase inhibitory activity and anti-inflammatory effect of some Tunisian medicinal plants},
journal = {South African Journal of Botany},
volume = {114},
pages = {84-88},
year = {2018},
issn = {0254-6299},
doi = {https://doi.org/10.1016/j.sajb.2017.10.019},
url = {https://www.sciencedirect.com/science/article/pii/S0254629917308839},
author = {H. Edziri and B. Marzouk and H. Mabrouk and M. Garreb and W. Douki and A. Mahjoub and L. Verschaeve and F. Najjar and M. Mastouri},
keywords = {Marrubium alysson, , , Butyrylcholinesterase inhibitory activity, Anti-inflammatory activity, Methanol extract},
abstract = {In the present study, we have tested the butyrylcholinesterase (BChE) inhibitory activity of the petroleum ether, ethyl acetate and methanol aerial extracts of Marrubium alysson, Peganum harmala and Retama raetam at 10 and 1000μg/mL. The anti-inflammatory activity was determined by the carrageenan-induced paw edema assay in rats. Total flavonoids and phenols and total pigment contents were also investigated. The highest flavonoid contents were found in the methanolic extracts of P. harmala and the highest phenol content in the methanolic extract of R. raetama. The highest concentration of chlorophyll a and b and carotenoids were found in the leaves of P. harmala. The methanol extract of Marrubium alysson showed the best inhibitory activity against BChE (72.5±2.07%) whereas the methanol extract of Peganum harmala had a moderate inhibitory effect (50.53±1.98%) at the same concentration of 1mg/ml. Methanol extracts of M. alysson and P. harmala had the highest anti-inflammatory activity.}
}
@article{ABDELRAHMAN2019216,
title = {Inline potentiometric monitoring of Butyrylcholinesterase activity based on metabolism of bambuterol at the point of care},
journal = {Sensors and Actuators B: Chemical},
volume = {285},
pages = {216-223},
year = {2019},
issn = {0925-4005},
doi = {https://doi.org/10.1016/j.snb.2019.01.055},
url = {https://www.sciencedirect.com/science/article/pii/S0925400519300760},
author = {Mohamed K. {Abd El-Rahman} and Sherif M. Eid and Mohamed R. Elghobashy and Khadiga M. Kelani},
keywords = {Point of care, Ion selective electrode, Bambuterol, ATR-FTIR, Butyrylcholinesterase enzyme activity, V and Michaelis-Menten constant},
abstract = {Globally, millions of patients are being exposed to anesthetics during surgeries. Butyrylcholinesterase (BChE) is the main metabolizing enzyme for these anesthetics. BChE silent activity defect, either acquired or genetic, may be life threatening due to apnea and respiratory paralysis. Hence, the development of point-of-care analytical methods for screening of BChE activity is of great importance to identify patients with BChE defect. This study describes the development of an ionophore-doped screen-printed ion selective electrode as a fast and simple method to efficiently achieve a continuous monitoring of the enzymatic hydrolysis of bambuterol (BAM) as substrate. BChE activity parameters (Vmax and Km) were calculated to be 1.7 × 10−8 mol min-1 ml-1 and 7.9 × 10-5 mol l-1, respectively, indicating high affinity of BChE towards BAM. A side by side comparison of the results obtained using the inline potentiometric approach and a recently published online ATR-FTIR method is presented to highlight the opportunities and challenges of each method. For clinical diagnostics, this approach provides a new platform for rapid determination of enzyme kinetics in real time and clearly identify patients that are susceptible to potentially lethal respiratory paralysis.}
}
@article{BOSAK2019101,
title = {Structural aspects of 4-aminoquinolines as reversible inhibitors of human acetylcholinesterase and butyrylcholinesterase},
journal = {Chemico-Biological Interactions},
volume = {308},
pages = {101-109},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.05.024},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719303916},
author = {Anita Bosak and Dejan M. Opsenica and Goran Šinko and Matija Zlatar and Zrinka Kovarik},
keywords = {Cholinesterase, Alzheimer's disease, p value, Quinoline-based compounds, Selectivity},
abstract = {Abstract
Eight derivatives of 4-aminoquinolines differing in the substituents attached to the C(4)-amino group and C(7) were synthesised and tested as inhibitors of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Both enzymes were inhibited by all of the compounds with inhibition constants (Ki) ranging from 0.50 to 50 μM exhibiting slight selectivity toward AChE over BChE. The most potent inhibitors of AChE were compounds with an n-octylamino chain or adamantyl group. The shortening of the chain length resulted in a decrease in AChE inhibition by 5–20 times. Docking studies revealed that the quinoline group within the AChE active site was positioned in the choline binding site, while the C(4)-amino group substituents, depending on their lipophilicity, could establish hydrogen bonds or π-interactions with residues of the peripheral anionic site. The most potent inhibitors of BChE were compounds with the most voluminous substituent on C(4)-amino group (adamantyl) or those with a stronger electron withdrawing substituent on C(7) (trifluormethyl group). Based on AChE inhibition, compounds with an n-octylamino chain or adamantyl substituent were shown to possess the capacity for further development as potential drugs for treatment of neurodegenerative diseases.}
}
@article{BUDRYN2018268,
title = {Evaluation of butyrylcholinesterase inhibitory activity by chlorogenic acids and coffee extracts assed in ITC and docking simulation models},
journal = {Food Research International},
volume = {109},
pages = {268-277},
year = {2018},
issn = {0963-9969},
doi = {https://doi.org/10.1016/j.foodres.2018.04.041},
url = {https://www.sciencedirect.com/science/article/pii/S0963996918303259},
author = {Grażyna Budryn and Joanna Grzelczyk and Andrzej Jaśkiewicz and Dorota Żyżelewicz and Horacio Pérez-Sánchez and José P. Cerón-Carrasco},
keywords = {Butyrylcholinesterase, Coffee, Chlorogenic acids, Hydroxycinnamic acids, ITC, Docking simulation},
abstract = {In patients with Alzheimer's disease (AD), elevated levels of butyrylcholinesterase (BChE) are observed. The enzyme hydrolyses acetylcholine, which shows deficiency in these patients. Therefore, BChE inhibitors are used in the treatment of Alzheimer's disease, especially synthetic ones, showing side effects with long-term intake. The sources of natural BChE inhibitors are constantly being sought. Coffee brews have been shown to reduce the symptoms of AD in epidemiological studies. However, the ability to inhibit BChE activity has not been investigated, depending on the degree of coffee roasting. The study was aimed at determining the interactions between BChE and the bioactive compounds of coffee and their ability to inhibit the activity of BChE. A comparison of individual bioactive compounds of coffee as well as extracts obtained from two main species, Arabica and Robusta, and additionally from different degrees of roasting was made. Two models were used: isothermal titration calorimetry (ITC) and molecular docking simulation. ITC analysis showed strong interactions of ferulic and dihydrocaffeic acids with BChE. These compounds are the metabolites of the chlorogenic acids, including both mono- and diesters of caffeic acid with quinic acid. Docking simulation showed their strong hydrophobic interaction with BChE, stabilized by hydrogen bonds and pi-pi interactions. After introducing acetylcholine into the model system, the strongest ability to inhibit hydrolytic activity of BChE was again observed for ferulic acid and additionally for 3-caffeoylquinic acid, and among coffee brews the most active were light roasted Arabica and green Robusta. The study was based on the physiological concentrations of coffee components, so the potential therapeutic effect of coffee infusions was proved.}
}
@article{NICHOLS2021152719,
title = {Reactivation of organophosphate-inhibited serum butyrylcholinesterase by novel substituted phenoxyalkyl pyridinium oximes and traditional oximes},
journal = {Toxicology},
volume = {452},
pages = {152719},
year = {2021},
issn = {0300-483X},
doi = {https://doi.org/10.1016/j.tox.2021.152719},
url = {https://www.sciencedirect.com/science/article/pii/S0300483X21000421},
author = {Royce H. Nichols and Janice E. Chambers},
keywords = {Organophosphorus compounds, Acetylcholinesterase and butyrylcholinesterase inhibitors, Oxime reactivators, Oxime assisted catalysis},
abstract = {Organophosphorus compounds (OPs) include nerve agents and insecticides that potently inhibit acetylcholinesterase (AChE), an essential enzyme found throughout the nervous system. High exposure levels to OPs lead to seizures, cardiac arrest, and death if left untreated. Oximes are a critical piece to the therapeutic regimen which remove the OP from the inhibited AChE and restore normal cholinergic function. The current oximes 2-PAM, MMB-4, TMB-4, HI-6, and obidoxime (OBD) have two drawbacks: lack of broad spectrum protection against multiple OP structures and poor brain penetration to protect against OP central neurotoxicity. An alternative strategy to enhance therapy is reactivation of serum butyrylcholinesterase (BChE). BChE is stoichiometrically inhibited by OPs with no apparent toxic result. Inhibition of BChE in the serum followed by reactivation could create a pseudo-catalytic scavenger allowing numerous regenerations of BChE to detoxify circulating OP molecules before they can reach target AChE. BChE in serum from rats, guinea pigs or humans was screened for the reactivation potential of our novel substituted phenoxyalkyl pyridinium oximes, plus 2-PAM, MMB-4, TMB-4, HI-6, and OBD (100μM) in vitro after inhibition by highly relevant surrogates of sarin, VX, and cyclosarin, and also DFP, and the insecticidal active metabolites paraoxon, phorate-oxon, and phorate-oxon sulfoxide. Novel oxime 15 demonstrated significant broad spectrum reactivation of OP-inhibited rat serum BChE while novel oxime 20 demonstrated significant broad spectrum reactivation of OP-inhibited human serum BChE. All tested oximes were poor reactivators of OP-inhibited guinea pig serum BChE. The bis-pyridinium oximes were poor BChE reactivators overall. BChE reactivation may be an additional mechanism to attenuate OP toxicity and contribute to therapeutic efficacy.}
}
@article{BRAID201966,
title = {Human umbilical cord perivascular cells: A novel source of the organophosphate antidote butyrylcholinesterase},
journal = {Chemico-Biological Interactions},
volume = {305},
pages = {66-78},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.03.022},
url = {https://www.sciencedirect.com/science/article/pii/S0009279718314431},
author = {Lorena R. Braid and Catherine A. Wood and Barry N. Ford},
keywords = {Butyrylcholinesterase, Human umbilical cord perivascular cells (HUCPVCs), Mesenchymal stromal cells (MSCs), Bioscavenger, Organophosphate, Production platform},
abstract = {Human butyrylcholinesterase (BChE) is a well-characterized bioscavenger with significant potential as a prophylactic or post-exposure treatment for organophosphate poisoning. Despite substantial efforts, BChE has proven technically challenging to produce in recombinant systems. Recombinant BChE tends to be insufficiently or incorrectly glycosylated, and consequently exhibits a truncated half-life, compromised activity, or is immunogenic. Thus, expired human plasma remains the only reliable source of the benchmark BChE tetramer, but production is costly and time intensive and presents possible blood-borne disease hazards. Here we report a human BChE production platform that produces functionally active, tetrameric BChE enzyme, without the addition of external factors such as polyproline peptides or chemical or gene modification required by other systems. Human umbilical cord perivascular cells (HUCPVCs) are a rich population of mesenchymal stromal cells (MSCs) derived from Wharton's jelly. We show that HUCPVCs naturally and stably secrete BChE during culture in xeno- and serum-free media, and can be gene-modified to increase BChE output. However, BChE secretion from HUCPVCs is limited by innate feedback mechanisms that can be interrupted by addition of miR 186 oligonucleotide mimics or by competitive inhibition of muscarinic cholinergic signalling receptors by addition of atropine. By contrast, adult bone marrow-derived mesenchymal stromal cells neither secrete measurable levels of BChE naturally, nor after gene modification. Further work is required to fully characterize and disable the intrinsic ceiling of HUCPVC-mediated BChE secretion to achieve commercially relevant enzyme output. However, HUCPVCs present a unique opportunity to produce both native and strategically engineered recombinant BChE enzyme in a human platform with the innate capacity to secrete the benchmark human plasma form.}
}
@article{MAJID2020445,
title = {Improvement of butyrylcholinesterase enzyme inhibition and medicinal properties of extracts of Aristotelia serrata leaves by ultrasound extraction},
journal = {Food and Bioproducts Processing},
volume = {124},
pages = {445-454},
year = {2020},
issn = {0960-3085},
doi = {https://doi.org/10.1016/j.fbp.2020.10.004},
url = {https://www.sciencedirect.com/science/article/pii/S0960308520305319},
author = {Hafiz Majid and Filipa V.M. Silva},
keywords = {Plant extracts, Ultrasound extraction, Optimization, Yield, Antioxidant activity, Alzheimer’s Disease},
abstract = {Aristotelia serrata, wineberry, or makomako, is a small deciduous fast-growing shrub of New Zealand that produces a berry. In this study leaf extracts were produced using ultrasound technology. Alzheimer’s Disease is a progressive mental deterioration related with ageing and senility, in which approved drugs for treatment inhibit butyrylcholinesterase (BChE), an enzyme present in the human brain. The ultrasound assisted extraction of natural anti-butyrylcholinesterase and antioxidants from this plant, and the yield of extraction were optimized using response surface methodology. The effect of acoustic power density (0.13–0.65 W/mL), time (1–20 min), and ethanol concentration (20–80%) on BChE inhibition, antioxidant activity, and extraction yield was determined, the optimum extraction conditions being 0.53 W/mL, 17.12 min and 74% ethanol. The optimized extracts were produced to experimentally validate the predicted responses. The IC50 concentrations were experimentally determined (26.2 μg/mL for BChE, 5.5 μg/mL for radical scavenging activity). A. serrata leaf extracts have potential to be used as complements to medicines traditionally used for memory dysfunction.}
}
@article{NAKAYAMA20173171,
title = {Synthesis, biochemical evaluation, and molecular modeling studies of aryl and arylalkyl di-n-butyl phosphates, effective butyrylcholinesterase inhibitors},
journal = {Bioorganic & Medicinal Chemistry},
volume = {25},
number = {12},
pages = {3171-3181},
year = {2017},
issn = {0968-0896},
doi = {https://doi.org/10.1016/j.bmc.2017.04.002},
url = {https://www.sciencedirect.com/science/article/pii/S0968089617300147},
author = {Kensaku Nakayama and Jason P. Schwans and Eric J. Sorin and Trina Tran and Jeannette Gonzalez and Elvis Arteaga and Sean McCoy and Walter Alvarado},
keywords = {Cholinesterase, Alzheimer’s disease, Organophosphates, Enzyme inhibition, Computational docking},
abstract = {A series of dialkyl aryl phosphates and dialkyl arylalkyl phosphates were synthesized. Their inhibitory activities were evaluated against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The di-n-butyl phosphate series consistently displayed selective inhibition of BChE over AChE. The most potent inhibitors of butyrylcholinesterase were di-n-butyl-3,5-dimethylphenyl phosphate (4b) [KI=1.0±0.4μM] and di-n-butyl 2-naphthyl phosphate (5b) [KI=1.9±0.4μM]. Molecular modeling was used to uncover three subsites within the active site gorge that accommodate the three substituents attached to the phosphate group. Phosphates 4b and 5b were found to bind to these three subsites in analogous fashion with the aromatic groups in both analogs being accommodated by the “lower region,” while the lone pairs on the PO oxygen atoms were oriented towards the oxyanion hole. In contrast, di-n-butyl-3,4-dimethylphenyl phosphate (4a) [KI=9±1μM], an isomer of 4b, was found to orient its aromatic group in the “upper left region” subsite as placement of this group in the “lower region” resulted in significant steric hindrance by a ridge-like region in this subsite. Future studies will be designed to exploit these features in an effort to develop inhibitors of higher inhibitory strength against butyrylcholinesterase.}
}
@article{XU2019232,
title = {A ratiometric fluorescence probe based on carbon dots for discriminative and highly sensitive detection of acetylcholinesterase and butyrylcholinesterase in human whole blood},
journal = {Biosensors and Bioelectronics},
volume = {131},
pages = {232-236},
year = {2019},
issn = {0956-5663},
doi = {https://doi.org/10.1016/j.bios.2019.02.031},
url = {https://www.sciencedirect.com/science/article/pii/S0956566319301381},
author = {Xiaoman Xu and Yao Cen and Guanhong Xu and Fangdi Wei and Menglan Shi and Qin Hu},
keywords = {Acetylcholinesterase, Butyrylcholinesterase, Discriminative detection, Carbon dots, Ratiometric fluorescence},
abstract = {A ratiometric fluorescence probe based on carbon dots (CDs) was developed for discriminative and highly sensitive detection of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activity in human whole blood. When o-phenylenediamine (OPD) was oxidized by Cu2+, the product 2,3-diaminophenazine (oxOPD) could effectively quench the fluorescence of CDs at 460 nm due to the inner filter effect and gave rise to a new emission peak at 570 nm. The AChE or BChE catalyzed hydrolysis reaction of acetylthiocholine or butyrylthiocholine to generate thiocholine, whose sulfhydryl group strongly captured Cu2+ to inhibit the oxidization of OPD, thus effectively preserving the natural fluorescence emission of CDs. The resulting fluorescence intensity ratio served as the signal output of the probe for cholinesterases (ChEs) activity sensing. The activities of AChE and BChE were determined to range from 0.2 to 14.0 U L−1 and from 0.1 to 5.0 U L−1, with detection limits of 0.1 U L−1 and 0.04 U L−1, respectively. Additionally, the IC50 of tacrine and ethopropazine for the inhibition of AChE and BChE were estimated to be 29.8 nM and 132.6 nM, respectively. Moreover, the probe was successfully applied to the discriminative determination of AChE and BChE in human whole blood without any pretreatment. These results suggested that the proposed strategy provided a discriminative, sensitive and robust analytical platform for ChEs clinical diagnostics and drug screening.}
}
@article{ROMANI20111584,
title = {Anandamide and its congeners inhibit human plasma butyrylcholinesterase. Possible new roles for these endocannabinoids?},
journal = {Biochimie},
volume = {93},
number = {9},
pages = {1584-1591},
year = {2011},
issn = {0300-9084},
doi = {https://doi.org/10.1016/j.biochi.2011.05.024},
url = {https://www.sciencedirect.com/science/article/pii/S0300908411001817},
author = {Rita Romani and Roberta Galeazzi and Gabriella Rosi and Rosamaria Fiorini and Irene Pirisinu and Annarina Ambrosini and Giovanna Zolese},
keywords = {Human plasma butyrylcholinesterase, Kinetic studies, Anandamide, Oleoylethanolamide, Palmitoylethanolamide},
abstract = {Butyrylcholinesterase (BChE), a serine hydrolase biochemically related to the cholinergic enzyme Acetylcholinesterase (AChE), is found in many mammalian tissues, such as serum and central nervous system, but its physiological role is still unclear. BChE is an important human plasma esterase, where it has detoxifying roles. Furthermore, recent studies suggest that brain BChE can have a role in Alzheimer’s disease (AD). The endocannabinoid arachidonoylethanolamide (anandamide) and other acylethanolamides (NAEs) are almost ubiquitary molecules and are physiologically present in many tissues, including blood and brain, where they show neuroprotective and anti-inflammatory properties. This paper demonstrates that they are uncompetitive (oleoylethanolamide and palmitoylethanolamide) or non competitive (anandamide) inhibitors of BChE (Ki in the range 1.32–7.48nM). On the contrary, NAEs are ineffective on AChE kinetic features. On the basis of the X-ray crystallographic structure of human BChE, and by using flexible docking procedures, an hypothesis on the NAE-BChE interaction is formulated by molecular modeling studies. Our results suggest that anandamide and the other acylethanolamides studied could have a role in the modulation of the physiological actions of BChE.}
}
@article{MACHAROEN2020107751,
title = {Simplified bioreactor processes for recombinant butyrylcholinesterase production in transgenic rice cell suspension cultures},
journal = {Biochemical Engineering Journal},
volume = {163},
pages = {107751},
year = {2020},
issn = {1369-703X},
doi = {https://doi.org/10.1016/j.bej.2020.107751},
url = {https://www.sciencedirect.com/science/article/pii/S1369703X20303053},
author = {Kantharakorn Macharoen and Karen A. McDonald and Somen Nandi},
keywords = {Butyrylcholinesterase, Plant cell suspension culture, Transgenic rice cell culture, Rice alpha-amylase 3D, Inducible promoter, Bioreactor operation},
abstract = {Metabolically regulated transgenic rice cell suspension culture has been developed aiming to be an efficient and cost-effective platform for production of rice-recombinant butyrylcholinesterase (rrBChE) that could be used as a bioscavenger enzyme against organophosphate nerve agents. In two-stage batch cultures, switching between growth and induction phases by exchanging media, the maximum active rrBChE levels were comparable among the bioreactor runs with controlled dissolved oxygen (DO) concentrations from 10–40% DO and without controlled DO at constant aeration rate. For a single-stage batch operation with no media exchange at 40% DO, production of rrBChE is triggered simply through sugar depletion due to the uptake of sugar by the cells, showing similar maximum active cell-associated rrBChE level compared to two-stage batch operations. However, the bioreactor process using uncontrolled DO, no media exchange, and half-concentration of sucrose resulted in a 1.4-fold increase in the maximum total active rrBChE (77 μg/g fresh weight) and 1.6-fold increase of total active rrBChE specific productivity (86 μg (g dry weight)−1 day−1) compared to the two-stage batch cultures. We found that monitoring the culture pH is a simple non-invasive technique that can help identify the start and progress of the induction phase in a single-stage culture. Altogether, we demonstrate a simplified, efficient, economical, and scalable bioreactor process for rrBChE production in metabolically regulated transgenic rice cell cultures.}
}
@article{LU2019117,
title = {Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation},
journal = {Bioorganic Chemistry},
volume = {85},
pages = {117-127},
year = {2019},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2018.12.023},
url = {https://www.sciencedirect.com/science/article/pii/S0045206818313026},
author = {Xin Lu and Hongyu Yang and Qihang Li and Yao Chen and Qi Li and You Zhou and Feng Feng and Wenyuan Liu and Qinglong Guo and Haopeng Sun},
keywords = {Selective butyrylcholinesterase, Pharmacophore modeling, Virtual screening, Molecular dynamics, Alzheimer’s disease},
abstract = {Butyrylcholinesterase (BChE) is recently considered as a new target for the treatment of Alzheimer’s disease (AD). There is an increasing interest in the development of BChE inhibitors. In the present study, a set of pharmacophore models for BChE was developed and validated. Based on the models, virtual screening was performed on five compound collections, from which seventeen potential hits were retained for biological investigation. In total, eight of these seventeen potential hits showed selective BChE inhibitory activity. Moreover, four compounds displayed IC50 values in sub-micromolar range on eqBChE and three displayed IC50 values < 2 μM on huBChE. The diverse scaffolds of the active compounds provided good starting point further development of selective BChE inhibitors. As far as we concerned, here we disclose the first selective pharmacophore model targeting BChE. The high rate of the model in the identification of active hits indicates it is a valuable tool for the development of selective BChE inhibitors, which may benefit the treatment of AD.}
}
@article{IMAI20201417,
title = {Effect of Calcium on the Hydrolysis Activity of Human Butyrylcholinesterase},
journal = {Journal of Pharmaceutical Sciences},
volume = {109},
number = {3},
pages = {1417-1420},
year = {2020},
issn = {0022-3549},
doi = {https://doi.org/10.1016/j.xphs.2019.12.006},
url = {https://www.sciencedirect.com/science/article/pii/S0022354919308123},
author = {Teruko Imai and Fatma Goksin Bahar and Kayoko Ohura and Akihisa Toda},
keywords = {drug metabolizing enzymes(s), enzyme(s), enzyme kinetics, hydrolysis, metabolism, phase I enzymes(s)},
abstract = {The aim of this experiment was to study the effects of calcium ion on the hydrolysis of cationic and anionic substrate by human butyrylcholinesterase (HuBChE). The hydrolysis of aspirin, an anionic substrate, by HuBChE was markedly increased in the presence of increasing concentrations of calcium ion (∼20 mM), as shown by the increasing kcat (∼18-fold). Butyrylthiocholine (BTC), a cationic substrate, was biphasically hydrolyzed with substrate activation; a second BTC molecule caused a 3-fold increase in kcat. At both lower and higher concentrations of BTC, its hydrolysis by HuBChE was slightly slowed down by the addition of calcium ion. Other cationic substrates, propranolol derivatives with butyryl and valeryl groups, were R-preferentially hydrolyzed by HuBChE; the rate of hydrolysis of these compounds was nearly the same in the absence and presence of calcium ion. These data indicate differential effects of calcium ion on HuBChE activity with anionic and cationic substrates. Furthermore, during the hydrolysis of aspirin in the presence of calcium ions, we demonstrated the existence of 2 additional binding sites for calcium, with Km values of 1.8 and 5.9 mM. These binding sites exhibited much lower affinities than the EF-hand motif, previously identified as a high-affinity calcium-binding site.}
}
@article{DEANDRADE2019931,
title = {Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease},
journal = {Bioorganic & Medicinal Chemistry},
volume = {27},
number = {6},
pages = {931-943},
year = {2019},
issn = {0968-0896},
doi = {https://doi.org/10.1016/j.bmc.2018.12.030},
url = {https://www.sciencedirect.com/science/article/pii/S0968089618318170},
author = {Peterson {de Andrade} and Susimaire P. Mantoani and Paulo Sérgio {Gonçalves Nunes} and Carlos Roca Magadán and Concepción Pérez and Danilo Jordão Xavier and Elza Tiemi Sakamoto Hojo and Nuria E. Campillo and Ana Martínez and Ivone Carvalho},
keywords = {Alzheimer's disease, Butyrylcholinesterase, Acetylcholinesterase, Click chemistry, Inhibitors and azido amino acids},
abstract = {Acetylcholinesterase (AChE) is the key enzyme targeted in Alzheimer's disease (AD) therapy, nevertheless butyrylcholinesterase (BuChE) has been drawing attention due to its role in the disease progression. Thus, we aimed to synthesize novel cholinesterases inhibitors considering structural differences in their peripheral site, exploiting a moiety replacement approach based on the potent and selective hAChE drug donepezil. Hence, two small series of N-benzylpiperidine based compounds have successfully been synthesized as novel potent and selective hBuChE inhibitors. The most promising compounds (9 and 11) were not cytotoxic and their kinetic study accounted for dual binding site mode of interaction, which is in agreement with further docking and molecular dynamics studies. Therefore, this study demonstrates how our strategy enabled the discovery of novel promising and privileged structures. Remarkably, compound 11 proved to be one of the most potent (0.17 nM) and selective (>58,000-fold) hBuChE inhibitor ever reported.}
}
@article{TVARIJONAVICIUTE2015262,
title = {Serum paraoxonase 1 and butyrylcholinesterase in dogs with hyperadrenocorticism},
journal = {The Veterinary Journal},
volume = {203},
number = {2},
pages = {262-263},
year = {2015},
issn = {1090-0233},
doi = {https://doi.org/10.1016/j.tvjl.2014.12.002},
url = {https://www.sciencedirect.com/science/article/pii/S1090023314004973},
author = {Asta Tvarijonaviciute and Marco Caldin and Silvia Martinez-Subiela and Fernando Tecles and Josep Pastor and Jose J. Ceron},
keywords = {Canine, Butyrylcholinesterase, Paraoxonase 1, Hyperadrenocorticism},
abstract = {The aim of this study was to evaluate serum activities of paraoxonase 1 (PON1) using three substrates; (1) 4-nitrophenylacetate (PON1n), (2) phenylacetate (PON1p), and (3) 5-thiobutyl butyrolactonase (PON1t), and butyrylcholinesterase (BChE) in dogs with hyperadrenocorticism (HAC). Serum activities of PON1 and BChE were higher in dogs with HAC than healthy dogs. There were strong positive correlations between PON1 activity measured with the three different substrates. This study demonstrated increased serum PON1 and BChE activities in dogs with HAC that could be attributed to the direct effect of glucocorticoids and lipid mobilisation.}
}
@article{SAKAYANATHAN20191147,
title = {In vitro and in silico analysis of novel astaxanthin-s-allyl cysteine as an inhibitor of butyrylcholinesterase and various globular forms of acetylcholinesterases},
journal = {International Journal of Biological Macromolecules},
volume = {140},
pages = {1147-1157},
year = {2019},
issn = {0141-8130},
doi = {https://doi.org/10.1016/j.ijbiomac.2019.08.168},
url = {https://www.sciencedirect.com/science/article/pii/S0141813019350263},
author = {Penislusshiyan Sakayanathan and Chitra Loganathan and Saravanan Kandasamy and Rajesh V. Ramanna and Kumaradhas Poomani and Palvannan Thayumanavan},
keywords = {Astaxanthin-s-allyl cysteine diester, Acetylcholinesterase, Butyrylcholinesterase, Cognitive dysfunction},
abstract = {In Alzheimer's disease (AD) and diabetes-associated cognitive decline, the acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activity is increased. AChE exists as different globular molecular forms: tetramer (G4), dimer (G2) and monomer (G1). In adult brain, G4 form is abundant however in AD, the ratio of lower molecular forms (G1) to G4 form increased. Hence, the present study delineated the inhibition of novel astaxanthin-s-allyl cysteine (AST-SAC) against BChE and various molecular forms of AChE. Cobra venom, human erythrocyte and Electrophorus electricus was used as source of G1, G2 and G4 form of AChE. AST-SAC showed inhibition against G1 (IC50 = 0.72 μM, competitive, Ki = 0.66 μM), G2 (IC50 = 0.65 μM, mixed, Ki = 0.50 μM) and G4 (IC50 = 0.67 μM, competitive, Ki = 0.67 μM) form of AChE. AST-SAC inhibited human brain AChE (IC50 = 0.84 μM, competitive, Ki = 0.53 μM) and human serum BChE (IC50 = 0.80 μM, competitive, Ki = 0.58 μM). In silico analysis revealed the interaction of AST-SAC with the amino acids present in peripheral anionic and catalytic site of human AChE and BChE. Molecular dynamics simulation confirmed the stable interaction of AST-SAC in the active site gorge of AChE and BChE.}
}
@article{ZEMAN2017548,
title = {The development of a butyrylcholinesterase porous pellet for innovative detection of cholinesterase inhibitors},
journal = {European Journal of Pharmaceutical Sciences},
volume = {109},
pages = {548-555},
year = {2017},
issn = {0928-0987},
doi = {https://doi.org/10.1016/j.ejps.2017.09.015},
url = {https://www.sciencedirect.com/science/article/pii/S0928098717305079},
author = {Jiří Zeman and David Vetchý and Aleš Franc and Sylvie Pavloková and Vladimír Pitschmann and Lukáš Matějovský},
keywords = {Pellets, Detection, Neusilin, Immobilization, Physostigmine, Sarin},
abstract = {The aim of the presented research was the preparation of an innovative carrier with significantly improved properties for the fast and sensitive detection of cholinesterase inhibitors such as nerve agents. This innovative carrier was in the form of spherical pellets containing different amounts of Neusilin. Neusilin is a synthetic and amorphous form of magnesium aluminometasilicate with a high specific surface area, and the immobilized enzyme butyrylcholinesterase with an activity of 50nkat·g−1. Pellets were prepared by the extrusion-spheronization method and dried in a hot air oven under two conditions – at 30°C for 72h and at 60°C for 24h. Dried pellets were consequently impregnated with a solution containing butyrylcholinesterase. Impregnated pellets were evaluated for their quality parameters, enzymatic activity and inhibition. Activity and inhibition were tested according to the standard Ellman's method. It was observed that the addition of Neusilin significantly increased the hardness, intraparticular porosity, sphericity and activity of the carriers as well as intensity of the color transition. Therefore it is shown that these carriers have unquestionable advantages over common carriers of their kind. Drying temperatures have been shown to have no effect on properties of pellets except for a change in their size. Results were confirmed by statistical evaluation using ANOVA and PCA.}
}
@article{HAMMOUDI2021129845,
title = {In silico drug discovery of Acetylcholinesterase and Butyrylcholinesterase enzymes inhibitors based on Quantitative Structure-Activity Relationship (QSAR) and drug-likeness evaluation},
journal = {Journal of Molecular Structure},
volume = {1229},
pages = {129845},
year = {2021},
issn = {0022-2860},
doi = {https://doi.org/10.1016/j.molstruc.2020.129845},
url = {https://www.sciencedirect.com/science/article/pii/S002228602032158X},
author = {Nour-El-Houda Hammoudi and Widad Sobhi and Ayoub Attoui and Tarek Lemaoui and Alessandro Erto and Yacine Benguerba},
keywords = { models, Acetylcholinesterase, Butyrylcholinesterase, drug-likeness, MLR Model},
abstract = {In the last years, in order to achieve a better treatment of Alzheimer's disease (AD), much focus has been put on the development of cholinesterase (Acetylcholinesterase and Butyrylcholinesterase) inhibitor drugs. Thus, the aim of this study is to discover promising active compounds for Acetylcholinesterase and Butyrylcholinesterase enzymes inhibitors based on QSAR model and drug-likeness evaluation. In this study, a series of DL0410 and its 50 derivatives are accounted for the set up of two QSAR models. This allows an exploration of the main molecular descriptors that control the inhibitory activity of specific compounds towards cholinesterase enzymes: Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE). Simultanerously, the models can help to predict the inhibitory activity of new compounds within its applicability domain. A Multiple Linear Regression (MLR) analysis is carried out to derive QSAR models. The results indicate that the QSAR models of Acetylcholinesterase and Butyrylcholinesterase inhibitory activity are robust and have a very good prediction capacity, testified by values of R2 equal to 0.935 and 0.895, respectively. The analysis carried out by adopting the QSAR models succeed in screening 15 potential compounds with higher biological activity. Subsequently, the investigated compounds has been subjected to the drug-likeness evaluation and reactivity study. The results show that most of the compounds do not present any bioavailability problem when administered orally. The results also allow determining the compounds that have not clearance problems, those that are the most stable and the most reactive among those tested. These findings indicate that the newly designed candidate drugs have promising potential toward AChE and BuChE enzyme inhibition and should be experimentally investigated.}
}
@article{KOBUSCISOWSKA20191,
title = {In vitro screening for acetylcholinesterase and butyrylcholinesterase inhibition and antimicrobial activity of chia seeds (Salvia hispanica)},
journal = {Electronic Journal of Biotechnology},
volume = {37},
pages = {1-10},
year = {2019},
issn = {0717-3458},
doi = {https://doi.org/10.1016/j.ejbt.2018.10.002},
url = {https://www.sciencedirect.com/science/article/pii/S0717345818300411},
author = {Joanna Kobus-Cisowska and Daria Szymanowska and Paulina Maciejewska and Dominik Kmiecik and Anna Gramza-Michałowska and Bartosz Kulczyński and Judyta Cielecka-Piontek},
keywords = {Acetylcholinesterase inhibition, Antimicrobial potential, Antioxidative properties, Butyrylcholinesterase inhibition, Chia seeds, Food additive, Phenolic acids and flavonols, Polyphenols, Prohealth, },
abstract = {Background
Chia seeds are gaining increasing interest among food producers and consumers because of their prohealth properties.
Results
The aim of this work was to evaluate the potential of chia seeds to act as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors. The highest inhibitory activity against AChE and BChE was observed for colored seed ethanol extracts. A positive correlation was found between the presence of quercetin and isoquercetin as well as protocatechuic, hydroxybenzoic, and coumaric acids and the activity of extracts as AChE and BChE inhibitors. It has also been shown that grain fragmentation affects the increase in the activity of seeds against cholinesterases (ChE). Furthermore, seeds have been shown to be a source of substances that inhibit microbial growth.
Conclusions
It was found that the chia seed extracts are rich in polyphenols and inhibit the activity of ChEs; therefore, their use can be considered in further research in the field of treatment and prevention of neurodegenerative diseases. How to cite: Kobus-Cisowska J, Szymanowska D, Maciejewska P, et al. In vitro screening for acetylcholinesterase and butyrylcholinoesterase inhibition and antimicrobial activity of chia seeds (Salvia hispanica). Electron J Biotechnol 2019;37. https://doi.org/10.1016/j.ejbt.2018.10.002}
}
@article{SYKAM2017204,
title = {Anticeramide antibody and butyrylcholinesterase in peripheral neuropathies},
journal = {Journal of Clinical Neuroscience},
volume = {42},
pages = {204-208},
year = {2017},
issn = {0967-5868},
doi = {https://doi.org/10.1016/j.jocn.2017.04.023},
url = {https://www.sciencedirect.com/science/article/pii/S0967586816307366},
author = {Aparna Sykam and V.R. Gutlapalli and Sandeep P. Tenali and A.K. Meena and Priscilla Chandran and Sujai Suneetha and Lavanya M. Suneetha},
keywords = {Autoantibodies, Butyrylcholinesterase, Leprosy, HIV, Diabetic, CIDP, Peripheral neuropathy},
abstract = {Ceramide is a glycosphingolipid, a component of nerve and non neuronal cell membrane and plays a role in maintaining the integrity of neuronal tissue. Butyrylcholinesterase (BChE) is a multifunctional enzyme, its involvement in neurodegenerative diseases has been well established. Anticeramide antibody (Ab-Cer) and enzyme BChE have been implicated in peripheral neuropathies. The present study investigates whether there is an association between Ab-Cer and BChE activities and peripheral neuropathies. Patients included: human immunodeficiency virus associated peripheral neuropathy (HIV-PN, n=39), paucibacillary leprosy (PB-L, n=36), multibacillary leprosy (MB-L, n=52), diabetic neuropathy (DN, n=22), demyelinating sensory motor polyneuropathy (DSMN, n=13) and chronic inflammatory demyelinating polyneuropathy (CIDP, n=10). Plasma Ab-Cer was measured by indirect enzyme linked immune assay (ELISA) and BChE activity in plasma was measured by colorimetric method. Ab-Cer levels were significantly elevated in MB-L and DN as compared to healthy subjects (HS). BChE levels were significantly higher in MB-L and DN as well as in HIV and HIV-PN. There is no significant difference in either Ab-Cer or BChE levels in DSMN and CIDP. Elevated plasma Ab-Cer and BChE levels may be considered significant in the pathogenesis of neuropathies. The variation in concurrent involvement of both the molecules in the neuropathies of the study, suggest their unique involvement in neurodegenerative pathways.}
}
@article{POMARA2019S79,
title = {CSF butyrylcholinesterase and acetylcholinesterase activity and their relationship to pro-inflammatory cytokines in late-life major depression},
journal = {European Neuropsychopharmacology},
volume = {29},
pages = {S79-S80},
year = {2019},
note = {Abstracts of the 31st ECNP Congress, 6 - 9 October 2018, Barcelona, Spain},
issn = {0924-977X},
doi = {https://doi.org/10.1016/j.euroneuro.2018.11.1060},
url = {https://www.sciencedirect.com/science/article/pii/S0924977X18319072},
author = {N. Pomara and D. Bruno and J. Nierenberg and C. Reichert and M. Fu and H. Zetterberg and K. Blennow}
}
@article{RIBAS201277,
title = {Reduction of butyrylcholinesterase activity in plasma from patients with disorders of propionate metabolism is prevented by treatment with L-carnitine and protein restriction},
journal = {Clinical Biochemistry},
volume = {45},
number = {1},
pages = {77-81},
year = {2012},
issn = {0009-9120},
doi = {https://doi.org/10.1016/j.clinbiochem.2011.10.017},
url = {https://www.sciencedirect.com/science/article/pii/S0009912011027032},
author = {Graziela S. Ribas and Emilene B. Scherer and Andrea G. Ferreira and Felipe Schmitz and Angela T. Wyse and Daiane Rodrigues and Sabrina Nascimento and Solange C. Garcia and Moacir Wajner and Carmen R. Vargas},
keywords = {Propionic acidemia, Methylmalonic acidemia, Malondialdehyde, Butyrylcholinesterase activity, L-carnitine, Oxidative damage, Free radicals},
abstract = {Objective
We investigated the relationship between butyrylcholinesterase (BuChE) activity and lipid oxidative damage in patients with disorders of propionate metabolism, before and after treatment with protein restriction and L-carnitine.
Design and methods
BuChE activity and malondialdehyde (MDA) were measured in plasma from eight untreated patients (at diagnosis) and from seven patients under treatment with protein restriction and L-carnitne supplementation (100mg/kg/day).
Results
We verified a significant reduction of butyrylcholinesterase activity, as well as an increased MDA formation in plasma from untreated patients. However, treated patients presented MDA and BuChE activity similar to controls. Furthermore, butyrylcholinesterase activity was negatively correlated with MDA concentrations in these patients.
Conclusion
The results suggest that an increased free radicals formation may be involved in the decrease of butyrylcholinesterase activity, possibly contributing to the neurological damage of these disorders, and that treatment with L-carnitine and low-protein diet possibly is able to prevent this damage.}
}
@article{PASIEKA2021113397,
title = {Discovery of multifunctional anti-Alzheimer’s agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters},
journal = {European Journal of Medicinal Chemistry},
volume = {218},
pages = {113397},
year = {2021},
issn = {0223-5234},
doi = {https://doi.org/10.1016/j.ejmech.2021.113397},
url = {https://www.sciencedirect.com/science/article/pii/S0223523421002464},
author = {Anna Pasieka and Dawid Panek and Jakub Jończyk and Justyna Godyń and Natalia Szałaj and Gniewomir Latacz and Julia Tabor and Eva Mezeiova and Fabien Chantegreil and José Dias and Damijan Knez and Junfeng Lu and Rongbiao Pi and Jan Korabecny and Xavier Brazzolotto and Stanislav Gobec and Georg Höfner and Klaus Wanner and Anna Więckowska and Barbara Malawska},
keywords = {Alzheimer’s disease, Multifunctional ligands, Inhibitors, Butyrylcholinesterase, BACE1, GABA transporters, Aβ aggregation},
abstract = {Looking for an effective anti-Alzheimer’s agent is very challenging; however, a multifunctional ligand strategy may be a promising solution for the treatment of this complex disease. We herein present the design, synthesis and biological evaluation of novel hydroxyethylamine derivatives displaying unique, multiple properties that have not been previously reported. The original mechanism of action combines inhibitory activity against disease-modifying targets: β-secretase enzyme (BACE1) and amyloid β (Aβ) aggregation, along with an effect on targets associated with symptom relief - inhibition of butyrylcholinesterase (BuChE) and γ-aminobutyric acid transporters (GATs). Among the obtained molecules, compound 36 exhibited the most balanced and broad activity profile (eeAChE IC50 = 2.86 μM; eqBuChE IC50 = 60 nM; hBuChE IC50 = 20 nM; hBACE1 IC50 = 5.9 μM; inhibition of Aβ aggregation = 57.9% at 10 μM; mGAT1 IC50 = 10.96 μM; and mGAT2 IC50 = 19.05 μM). Moreover, we also identified 31 as the most potent mGAT4 and hGAT3 inhibitor (IC50 = 5.01 μM and IC50 = 2.95 μM, respectively), with high selectivity over other subtypes. Compounds 36 and 31 represent new anti-Alzheimer agents that can ameliorate cognitive decline and modify the progress of disease.}
}
@article{MA2020121278,
title = {Rational design of a near-infrared fluorescence probe for highly selective sensing butyrylcholinesterase (BChE) and its bioimaging applications in living cell},
journal = {Talanta},
volume = {219},
pages = {121278},
year = {2020},
issn = {0039-9140},
doi = {https://doi.org/10.1016/j.talanta.2020.121278},
url = {https://www.sciencedirect.com/science/article/pii/S0039914020305695},
author = {Jianlong Ma and Xiaofeng Lu and Honglin Zhai and Qiang Li and Li Qiao and Yong Guo},
keywords = {Fluorescent probe, Rational design, Highly selective, Butyrylcholinesterase},
abstract = {In the current work, a near-infrared (NIR) fluorescent probe (CyClCP) was developed for fast (35 min), highly sensitive (LOD of 3.75 U/L) and selective response to BChE in vitro and in vivo. Upon the addition of BChE, CyClCP could be efficiently activated with remarkable NIR (λem = 708 nm) fluorescence enhancement and obvious absorbance red shift (581 nm–687 nm). Specifically, according to the subtle differences structural features and substrate preference between BChE and its sister enzyme AChE, CyClCP was constructed by introducing chlorine atom at the ortho-position of the phenolic hydroxyl in the previous reported probe (CyCP). Fortunately, CyClCP exhibited better selectivity towards BChE over AChE compared with CyCP. This molecular design strategy was further rationalized by docking molecular of fluorescence probes (CyClCP and CyCP) and enzymes (BChE and AChE). Finally, CyClCP was membrane permeable and successfully applied to image endogenous BChE level in HepG2 and LO2 cells. Therefore, CyClCP could serve as a promising tool for BChE-related physiological function studies in complex biological systems.}
}
@article{LOESCHE2019103092,
title = {Novel 12-hydroxydehydroabietylamine derivatives act as potent and selective butyrylcholinesterase inhibitors},
journal = {Bioorganic Chemistry},
volume = {90},
pages = {103092},
year = {2019},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2019.103092},
url = {https://www.sciencedirect.com/science/article/pii/S0045206819300215},
author = {Anne Loesche and Jana Wiemann and Matthias Rohmer and Wolfgang Brandt and René Csuk},
abstract = {The skeleton of the diterpene dehydroabietylamine was modified, and a set of 12-hydroxy-dehydroabietylamine derivatives was obtained. The compounds were screened in colorimetric Ellman’s assays to determine their ability to act as inhibitors for the enzymes acetylcholinesterase (AChE, from electric eel) and butyrylcholinesterase (BChE, from equine serum). Additional investigations concerning the enzyme kinetics were performed and showed 12-hydroxy-N-(4-nitro-benzoyl)dehydroabietylamine (13) and 12-hydroxy-N-(isonicotinoyl)dehydroabietylamine (17) as selective BChE inhibitors holding good inhibition constants Ki = 0.72 ± 0.06 μM and Ki = 0.86 ± 0.19 μM, respectively.}
}
@article{LOCKRIDGE2018109,
title = {Purification of recombinant human butyrylcholinesterase on Hupresin®},
journal = {Journal of Chromatography B},
volume = {1102-1103},
pages = {109-115},
year = {2018},
issn = {1570-0232},
doi = {https://doi.org/10.1016/j.jchromb.2018.10.026},
url = {https://www.sciencedirect.com/science/article/pii/S157002321831451X},
author = {Oksana Lockridge and Emilie David and Lawrence M. Schopfer and Patrick Masson and Xavier Brazzolotto and Florian Nachon},
keywords = {Hupresin®, Affinity chromatography, Procainamide-Sepharose, Butyrylcholinesterase, Acetylcholinesterase},
abstract = {Affinity chromatography on procainamide-Sepharose has been an important step in the purification of butyrylcholinesterase (BChE) and acetylcholinesterase (AChE) since its introduction in 1978. The procainamide affinity gel has limitations. In the present report a new affinity gel called Hupresin® was evaluated for its ability to purify truncated, recombinant human butyrylcholinesterase (rHuBChE) expressed in a stably transfected Chinese Hamster Ovary cell line. We present a detailed example of the purification of rHuBChE secreted into 3940 mL of serum-free culture medium. The starting material contained 13,163 units of BChE activity (20.9 mg). rHuBChE was purified to homogeneity in a single step by passage over 82 mL of Hupresin® eluted with 0.1 M tetramethylammonium bromide in 20 mM TrisCl pH 7.5. The fraction with the highest specific activity of 630 units/mg contained 11 mg of BChE. Hupresin® is superior to procainamide-Sepharose for purification of BChE, but is not suitable for purifying native AChE because Hupresin® binds AChE so tightly that AChE is not released with buffers, but is desorbed with denaturing solvents such as 50% acetonitrile or 1% trifluoroacetic acid. Procainamide-Sepharose will continue to be useful for purification of AChE.}
}
@article{VAFADARNEJAD2019103192,
title = {Novel N-benzylpyridinium moiety linked to arylisoxazole derivatives as selective butyrylcholinesterase inhibitors: Synthesis, biological evaluation, and docking study},
journal = {Bioorganic Chemistry},
volume = {92},
pages = {103192},
year = {2019},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2019.103192},
url = {https://www.sciencedirect.com/science/article/pii/S0045206819307242},
author = {Fahimeh Vafadarnejad and Elahe Karimpour-Razkenari and Bilqees Sameem and Mina Saeedi and Omidreza Firuzi and Najmeh Edraki and Mohammad Mahdavi and Tahmineh Akbarzadeh},
keywords = {Acetylcholinesterase, Butyrylcholinesterase, Docking study, Kinetic study, Neuroprotectivity, Pyridinium salts, β-secretase (BACE1)},
abstract = {A novel series of N-benzylpyridinium moiety linked to arylisoxazole ring were designed, synthesized, and evaluated for their in vitro acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. Synthesized compounds were classified into two series of 5a-i and 5j-q considering the position of positively charged nitrogen of pyridinium moiety (3- or 4- position, respectively) connected to isoxazole carboxamide group. Among the synthesized compounds, compound 5n from the second series of compounds possessing 2,4-dichloroaryl group connected to isoxazole ring was found to be the most potent AChE inhibitor (IC50 = 5.96 µM) and compound 5j also from the same series of compounds containing phenyl group connected to isoxazole ring demonstrated the most promising inhibitory activity against BChE (IC50 = 0.32 µM). Also, kinetic study demonstrated competitive inhibition mode for both AChE and BChE inhibitory activity. Docking study was also performed for those compounds and desired interactions with those active site amino acid residues were confirmed through hydrogen bonding as well as π-π and π-anion interactions. In addition, the most potent compounds were tested against BACE1 and their neuroprotectivity on Aβ-treated neurotoxicity in PC12 cells which depicted negligible activity. It should be noted that most of the synthesized compounds from both categories 5a-i and 5j-q showed a significant selectivity toward BChE. However, series 5j-q were more active toward AChE than series 5a-i.}
}
@article{KANGUR2019107,
title = {Structural stability of human butyrylcholinesterase under high hydrostatic pressure},
journal = {Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics},
volume = {1867},
number = {2},
pages = {107-113},
year = {2019},
issn = {1570-9639},
doi = {https://doi.org/10.1016/j.bbapap.2018.11.001},
url = {https://www.sciencedirect.com/science/article/pii/S1570963918301997},
author = {Liina Kangur and Kõu Timpmann and Dominik Zeller and Patrick Masson and Judith Peters and Arvi Freiberg},
abstract = {Human butyrylcholinesterase is a nonspecific enzyme of clinical, pharmacological and toxicological significance. Although the enzyme is relatively stable, its activity is affected by numerous factors, including pressure. In this work, hydrostatic pressure dependence of the intrinsic tryptophan fluorescence in native and salted human butyrylcholinesterase was studied up to the maximum pressure at ambient temperature of about 1200 MPa. A correlated large shift toward long wavelengths and broadening observed at pressures between 200 and 700 MPa was interpreted as due to high pressure-induced denaturation of the protein, leading to an enhanced exposure of tryptophan residues into polar solvent environment. This transient process in native butyrylcholinesterase presumably involves conformational changes of the enzyme at both tertiary and secondary structure levels. Pressure-induced mixing of emitting local indole electronic transitions with quenching charge transfer states likely describes the accompanying fluorescence quenching that reveals different course from spectral changes. All the pressure-induced changes turned irreversible after passing a mid-point pressure of about 400 ± 50 MPa. Addition of either 0.1 M ammonium sulphate (a kosmotropic salt) or 0.1 M lithium thiocyanate (a chaotropic salt) to native enzyme similarly destabilized its structure.}
}
@article{CASTRO2018301,
title = {Oxidation at C-16 enhances butyrylcholinesterase inhibition in lupane triterpenoids},
journal = {Bioorganic Chemistry},
volume = {79},
pages = {301-309},
year = {2018},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2018.05.012},
url = {https://www.sciencedirect.com/science/article/pii/S0045206818301974},
author = {María Julia Castro and Victoria Richmond and María Belén Faraoni and Ana Paula Murray},
keywords = {Cholinesterase inhibitors, Lupane derivatives, Triterpenoids, Molecular modeling},
abstract = {A set of triterpenoids with different grades of oxidation in the lupane skeleton were prepared and evaluated as cholinesterase inhibitors. Allylic oxidation with selenium oxide and Jones’s oxidation were employed to obtain mono-, di- and tri-oxolupanes, starting from calenduladiol (1) and lupeol (3). All the derivatives showed a selective inhibition of butyrylcholinesterase over acetylcholinesterase (BChE vs. AChE). A kinetic study proved that compounds 2 and 9, the more potent inhibitors of the series, act as competitive inhibitors. Molecular modeling was used to understand their interaction with BChE, the role of carbonyl at C-16 and the selectivity towards this enzyme over AChE. These results indicate that oxidation at C-16 of the lupane skeleton is a key transformation in order to improve the cholinesterase inhibition of these compounds.}
}
@article{BONDZIC2020110990,
title = {Aminoalcoholate-driven tetracopper(II) cores as dual acetyl and butyrylcholinesterase inhibitors: Experimental and theoretical elucidation of mechanism of action},
journal = {Journal of Inorganic Biochemistry},
volume = {205},
pages = {110990},
year = {2020},
issn = {0162-0134},
doi = {https://doi.org/10.1016/j.jinorgbio.2019.110990},
url = {https://www.sciencedirect.com/science/article/pii/S0162013419305860},
author = {Aleksandra M. Bondžić and Milan V. Senćanski and Ana V. {Vujačić Nikezić} and Marina V. Kirillova and Vânia André and Alexander M. Kirillov and Bojan P. Bondžić},
keywords = {AChE, BuChE, Dual inhibitors, Docking studies},
abstract = {Three coordination compounds featuring different types of tetracopper(II) cores, namely [O ⊂ Cu4{N(CH2CH2O)3}4(BOH)4][BF4]2 (1), [Cu4(μ4-H2edte)(μ5-H2edte)(sal)2]n·7nH2O, (H4edte = N,N,N′,N′-tetrakis(2-hydroxyethyl)ethylenediamine, H2sal = salicylic acid) (2), and [{Cu4(μ3-Hbes)4(μ-hba)}K(H2O)3]n, H3bes = N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (3), were assayed for their potency to inhibit the acetyl (AChE) and butyrylcholinesterase (BuChE) enzymes aiming to test these compounds as potential dual inhibitors in the treatment of Alzheimer's disease. All the investigated compounds showed a strong inhibitory potency toward both enzymes with IC50 values in micromolar range of concentration; compound 1 displayed the most potent inhibitory behaviour toward both enzymes. The mechanism of the AChE and BuChE inhibition was examined by enzyme kinetic measurements. The obtained kinetic parameters, Vmax and Km indicated an uncompetitive type of inhibition of both enzymes by compound 1. For the other two compounds a non-competitive inhibition mode was observed. To get further insight into the mechanism of action and to elucidate binding modes in details we examined the interactions of 1–3 with acetylcholinesterase, using molecular docking approach. Grid based docking studies indicated that these compounds can bind to peripheral anionic site (PAS) of the AChE with Ki values in micromolar range. Moreover, blind docking revealed the capability of investigated compounds to bind to new allosteric site (i.e. binding site II) distinct from PAS. Showing that these Cu-based compounds can act as new allosteric inhibitors of AChE and identifying novel allosteric binding site on AChE represents a significant contribution toward the design of novel and more effective inhibitors of AChE.}
}
@article{ONDER2019108845,
title = {The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by methylene violet 3RAX},
journal = {Chemico-Biological Interactions},
volume = {314},
pages = {108845},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.108845},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719311354},
author = {Seda Onder and Kevser Biberoglu and Ozden Tacal},
keywords = {Acetylcholinesterase, Butyrylcholinesterase, Methylene violet 3RAX, Cholinesterase inhibition},
abstract = {Phenazines, naturally produced by bacteria and archaeal Methanosarcina species are nitrogen-containing tricyclic molecules with antibiotic, antitumoral, and antiparasitic activities. Phenazines are used as electron acceptors-donors in wide range of fields including environmental biosensors. In this study, the inhibitory effects of a synthetic phenazine dye, methylene violet 3RAX (also known as diethyl safranine) on human erythrocyte AChE and human plasma BChE were tested and also its inhibitory mechanisms for both enzymes were studied in detail. Kinetic analyses showed that methylene violet 3RAX acts as a hyperbolic noncompetitive inhibitor of AChE with Ki value of 1.58 ± 0.36 μM; α = 1; β = 0.12 ± 0.0003. On the other hand, it caused linear competitive inhibition of BChE with Ki value of 0.51 ± 0.006 μM; α = ∞. In conclusion, methylene violet 3RAX which is a highly effective inhibitor of both human AChE and human BChE with Ki values in low micromolar range may be a promising candidate for the treatment of Alzheimer's disease.}
}
@article{DEBAY2019P112,
title = {SYNTHESIS AND IN VIVO BRAIN PET EVALUATION OF 1-METHYL-4-PIPERIDYL P-18[F]FLOUROBENZOATE (TRV6501): A BUTYRYLCHOLINESTERASE-SPECIFIC RADIOLIGAND FOR ALZHEIMER’S DISEASE},
journal = {Alzheimer's & Dementia},
volume = {15},
number = {7, Supplement },
pages = {P112},
year = {2019},
note = {Alzheimer’s Association International Conference 2019},
issn = {1552-5260},
doi = {https://doi.org/10.1016/j.jalz.2019.06.4250},
url = {https://www.sciencedirect.com/science/article/pii/S1552526019344164},
author = {Drew R. DeBay and Ian Pottie and Andrew G. Reid and Earl Martin and Antoun Boulaouz and Steve Burrell and Chris V. Bowen and Sultan Darvesh}
}
@article{CAO2021129348,
title = {A highly butyrylcholinesterase selective red-emissive mitochondria-targeted fluorescent indicator imaging in liver tissue of mice},
journal = {Sensors and Actuators B: Chemical},
volume = {330},
pages = {129348},
year = {2021},
issn = {0925-4005},
doi = {https://doi.org/10.1016/j.snb.2020.129348},
url = {https://www.sciencedirect.com/science/article/pii/S0925400520316889},
author = {Ting Cao and Lei Zheng and Liang Zhang and Zhidong Teng and Jing Qian and Hong Ma and Jiemin Wang and Yuping Cao and Wenwu Qin and Yun Liu},
keywords = {Butyrylcholinesterase, Fluorescence probe, Mitochondria-targeted, Imaging in vitro and in vivo, Liver tissue},
abstract = {A long-emitting (λex = 580 nm, λem = 628 nm) mitochondrial targeting butyrylcholinesterase (BChE) selective fluorescent chemosensor (BChE-NBD) has been synthesized. A prominent fluorescence enhancement only for BChE was found in aqueous solution. BChE-NBD has low biological toxicity and has been successfully applied to the detection and imaging of BChE in mitochondria in a variety of cells and not interfered by other analytes (especially acetylcholinesterase). More importantly, imaging study of the distribution of the BChE in mice was performed first time, which confirmed the widespread existence of the enzyme in liver tissue. This making the probe BChE-NBD hopeful to be an effective tool for investigates liver diseases in basic medicine and clinical applications.}
}
@article{ABDULLAHA2020112761,
title = {Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase},
journal = {European Journal of Medicinal Chemistry},
volume = {207},
pages = {112761},
year = {2020},
issn = {0223-5234},
doi = {https://doi.org/10.1016/j.ejmech.2020.112761},
url = {https://www.sciencedirect.com/science/article/pii/S0223523420307339},
author = {Mohd Abdullaha and Vijay K. Nuthakki and Sandip B. Bharate},
keywords = {Alzheimer’s disease, e-pharmacophore modeling, 1-Benzylpiperidine benzamide, Acetylcholinesterase, Butyrylcholinesterase},
abstract = {The cholinesterase enzymes play a vital role in maintaining balanced levels of the neurotransmitter acetylcholine in the central nervous system. However, the overexpression of these enzymes results in hampered neurotransmission. Both the major forms of cholinesterase enzymes viz. acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) play a crucial role in blocking neurotransmission; therefore, in recent years, a strategy of dual cholinesterase inhibition is being explored. Herein, we developed an energy-optimized e-pharmacophore hypothesis AHHPRR from AChE-donepezil complex and screened a set of 15 scaffolds that were designed imaginarily. The ligand with N-(1-benzylpyridinium) benzamide framework has shown the highest fitness and volume score, which was chosen for synthesis and validation. A series of pyridinium benzamides were synthesized and screened for cholinesterase inhibition that led to the identification of 7b, a naphthalene containing N-(1-benzylpiperidine) benzamide as a potent dual AChE and BChE inhibitor with IC50 values of 0.176, and 0.47 μM, respectively. The kinetic study indicated that 7b inhibits AChE in a non-competitive manner with Ki value of 0.21 μM, and BChE in a mixed-fashion with Ki of 0.15 μM. The observed mode of inhibition was corroborated with molecular docking studies. The MD simulation studies pointed out that both AChE and BChE undergo low conformational changes in complex with 7b. The benzamide 7b displayed high BBB permeability in PAMPA assay, which indicates its potential for further exploration in preclinical studies for Alzheimer’s disease.}
}
@article{JING2019629,
title = {Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors},
journal = {Drug Discovery Today},
volume = {24},
number = {2},
pages = {629-635},
year = {2019},
issn = {1359-6446},
doi = {https://doi.org/10.1016/j.drudis.2018.11.012},
url = {https://www.sciencedirect.com/science/article/pii/S1359644618303337},
author = {Lanlan Jing and Gaochan Wu and Dongwei Kang and Zhongxia Zhou and Yuning Song and Xinyong Liu and Peng Zhan},
abstract = {Butyrylcholinesterase (BChE) is considered a promising drug target for the treatment of moderate to severe Alzheimer’s disease (AD). Here, we review medicinal-chemistry strategies that are currently available for the discovery of selective BChE inhibitors.}
}
@article{CAMPELLO2020102066,
title = {Correlation of plasma butyrylcholinesterase concentration with Acethylcholinesterase H353N polymorphism in the inflammatory response of Chagas disease patients},
journal = {Parasitology International},
volume = {76},
pages = {102066},
year = {2020},
issn = {1383-5769},
doi = {https://doi.org/10.1016/j.parint.2020.102066},
url = {https://www.sciencedirect.com/science/article/pii/S1383576920300167},
author = {A.C. Campello and L.G.F.A.B.D.E. Zanella and R.B. Suzuki and M.O. Tokumo and E.F.B. Chagas and W. Baleotti and M.A. Sperança and L.P.A. Martins},
keywords = {, Chagas disease, Butyrylcholinesterase, Acetylcholinesterase, Blood group genotyping},
abstract = {Trypanosoma cruzi infection triggers an intense production of pro-inflammatory cytokines mediated by T helper 1 lymphocytes, inducing the anti-inflammatory reflex of acetylcholine (ACh). The ACh concentration modulation is associated to the two major esterases, the acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). AChE H353N protein polymorphism is related to low Chagas chronic disease prognostic. In order to evaluate the correlation of plasmatic BuChE concentration and the presence of AChE H353N polymorphism in Chagas disease patients and healthy individuals, we studied two groups of individuals, one of 61 Chagas disease patients and another of 74 healthy individuals. Plasma concentration of BuChE was measured by the chemiluminescent method and AChE H353N polymorphism was investigated by PCR-RFLP and sequencing of the respective encoding AChE gene fragment. The BuChE concentration was statistically higher in Chagas disease patients, with no AChE genotype significant influence. AChE genotypes YT*A/YT*A, YT*A/YT*B and YT*B/YT*B, respectively, were expressed in 53 (86.88%), 7 (11.46%) and one (1.64%) chagasic patients, and in 68 (91.89%), 6 (8.10%) and none healthy individuals. BuChE activity may represent an important marker for chronic Chagas disease inflammatory process and prognostic. Lower BuChE concentration correlated with AChE YT*B allele, although without statistical power.}
}
@article{JIANG2019278,
title = {Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer's disease},
journal = {Phytomedicine},
volume = {54},
pages = {278-290},
year = {2019},
issn = {0944-7113},
doi = {https://doi.org/10.1016/j.phymed.2018.09.199},
url = {https://www.sciencedirect.com/science/article/pii/S0944711318304847},
author = {Yingying Jiang and Hongwei Gao},
keywords = {Alzheimer's disease (AD), Butyrylcholinesterase (BChE), Flavonoids, Pharmacophore models, Molecular docking,  evolution},
abstract = {Background
Alzheimer's disease is a severe neurodegenerative disease of the central nervous system in the elderly.
Hypothesis/Purpose
In our study, we aimed to find the best potential small molecule for AD treatment.
Study design
We used many models in Discovery Studio 2016 to find new potential inhibitors of butyrylcholinesterase (BChE), including pharmacophore model, virtual screening model, molecular docking model, de novo evolution model.
Methods
Ligand-based pharmacophore models were used to identify the critical chemical features of BChE inhibitors using the module of 3D QSAR Pharmacophore Generation in Discovery Studio 2016. The best pharmacophore model was then validated by cost analysis, Fischer's randomization method, 3D-QSAR Method of the training set and test set. The compounds that match the best pharmacophore model with the predicted activity <1 μM filtered by Lipinski's rule of five were subjected to molecular docking.
Result
After virtual screening, 35 compounds filtered by Lipinski's rule of five and ADMET analysis were subjected to molecular docking and then the number were narrowed down on 10 compounds based on -CDOCKER_ENERGY. Finally, we obtained and modified the best potential candidate ENA739155.
Conclusion
Ultimately, ENA739155_Evo with -CDOCKER_ENERGY of 47.12, estimate activity of 0.012, fit value of 10.02 could be further subjected to drug development and forwarded as better alternatives to the current batch of medicines used for the treatment of AD.}
}
@article{MULITA2021e13,
title = {Value of butyrylcholinesterase as a marker of surgical site infection following surgery for colorectal cancer},
journal = {European Journal of Surgical Oncology},
volume = {47},
number = {1},
pages = {e13-e14},
year = {2021},
note = {Peritoneal Surface Malignancies},
issn = {0748-7983},
doi = {https://doi.org/10.1016/j.ejso.2020.11.070},
url = {https://www.sciencedirect.com/science/article/pii/S0748798320309677},
author = {Francesk Mulita and Elias Liolis and Nikoleta Oikonomou and Levan Tchabashvili and Ioannis Maroulis and George Panos}
}
@article{MILES2020127609,
title = {Rapid discovery of a selective butyrylcholinesterase inhibitor using structure-based virtual screening},
journal = {Bioorganic & Medicinal Chemistry Letters},
volume = {30},
number = {24},
pages = {127609},
year = {2020},
issn = {0960-894X},
doi = {https://doi.org/10.1016/j.bmcl.2020.127609},
url = {https://www.sciencedirect.com/science/article/pii/S0960894X20307204},
author = {Jared A. Miles and Jeevak S. Kapure and Girdhar Singh Deora and Charlotte Courageux and Alexandre Igert and José Dias and Ross P. McGeary and Xavier Brazzolotto and Benjamin P. Ross},
keywords = {Alzheimer’s disease, Butyrylcholinesterase, Inhibitor, Virtual screening},
abstract = {Acetylcholinesterase inhibitors are the mainstay of Alzheimer's disease treatments, despite having only short-term symptomatic benefits and severe side effects. Selective butyrylcholinesterase inhibitors (BuChEIs) may be more effective treatments in late-stage Alzheimer’s disease with fewer side effects. Virtual screening is a powerful tool for identifying potential inhibitors in large digital compound databases. This study used structure-based virtual screening combined with physicochemical filtering to screen the InterBioScreen and Maybridge databases for novel selective BuChEIs. The workflow rapidly identified 22 potential hits in silico, resulting in the discovery of a human BuChEI with low-micromolar potency in vitro (IC50 2.4 µM) and high selectivity for butyrylcholinesterase over acetylcholinesterase. The compound was a rapidly reversible BuChEI with mixed-model in vitro inhibition kinetics. The binding interactions were investigated using in silico molecular dynamics and by developing structure-activity relationships using nine analogues. The compound also displayed high permeability in an in vitro model of the blood-brain barrier.}
}
@article{ARGUEDAS2019e02620,
title = {Differences in plasmatic butyrylcholinesterases (BChE) values between Pacific and Caribbean populations of terciopelo (Bothrops asper) in Costa Rica},
journal = {Heliyon},
volume = {5},
number = {10},
pages = {e02620},
year = {2019},
issn = {2405-8440},
doi = {https://doi.org/10.1016/j.heliyon.2019.e02620},
url = {https://www.sciencedirect.com/science/article/pii/S2405844019362802},
author = {Randall Arguedas and Aarón Gómez and Paloma Alcázar and Danilo Chacón and Greivin Corrales and Marco D. Barquero},
keywords = {Biochemistry, Ecology, Toxicology, Wildlife ecology, Environmental toxicology, Veterinary medicine, Animal behavior, Snakes, Hematology, Esterase, Organophosphates},
abstract = {The terciopelo (Bothrops asper) inhabits human-modified environments such as agricultural areas, becoming more prone to be exposed to organophosphate insecticides. These chemicals can inhibit plasmatic butyrylcholinesterases (BChE) activity in B. asper. Caribbean and Pacific populations of B. asper belong to two divergent lineages that exhibit robust genetic partitioning; however, differences across versants in biochemistry and hematology have not yet been examined, especially in BChE variations. This study aims to evaluate the differences of BChE plasmatic values, hematology parameters, and some biochemical analytes as biomarkers in the presence of organophosphates between the Pacific and Caribbean population of B. asper in Costa Rica. A total of 89 snakes (41 Pacific and 48 Caribbean) were used, and hematology parameter, albumin, aspartate aminotransferase (AST), total protein and BChEs were evaluated. Differences in hemoglobin content, thrombocytes, white cell count, AST, and BChE values were found between both versants. Intrinsic genetic factors might influence the variation found in BChE and AST values in the snakes sampled from both versants; moreover, understanding this variation in BChE and AST values across the B. asper's distribution can be useful in future ecotoxicology, biomonitoring, genetic and other clinical/health studies.}
}
@article{KUMAR2020107355,
title = {In silico modeling for dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzymes in Alzheimer’s disease},
journal = {Computational Biology and Chemistry},
volume = {88},
pages = {107355},
year = {2020},
issn = {1476-9271},
doi = {https://doi.org/10.1016/j.compbiolchem.2020.107355},
url = {https://www.sciencedirect.com/science/article/pii/S1476927120304369},
author = {Vinay Kumar and Achintya Saha and Kunal Roy},
keywords = {2D-QSAR, PLS, AChE, BuChE, Selectivity, Docking},
abstract = {In this research, we have implemented two-dimensional quantitative structure-activity relationship (2D-QSAR) modeling using two different datasets, namely, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) enzyme inhibitors. A third dataset has been derived based on their selectivity and used for the development of partial least squares (PLS) based regression models. The developed models were extensively validated using various internal and external validation parameters. The features appearing in the model against AChE enzyme suggest that a small ring size, higher number of −CH2- groups, higher number of secondary aromatic amines and higher number of aromatic ketone groups may contribute to the inhibitory activity. The features obtained from the model against BuChE enzyme suggest that the sum of topological distances between two nitrogen atoms, higher number of fragments X-C(=X)-X, higher number of secondary aromatic amides, fragment R--CR-X may be more favorable for inhibition. The features obtained from selectivity based model suggest that the number of aromatic ethers, unsaturation content relative to the molecular size and molecular shape may be more specific for the inhibition of the AChE enzyme in comparison to the BuChE enzyme. Moreover, we have implemented the molecular docking studies using the most and least active molecules from the datasets in order to identify the binding pattern between ligand and target enzyme. The obtained information is then correlated with the essential structural features associated with the 2D-QSAR models.}
}
@article{WAJID20194030,
title = {Microwave-Assisted Organic Synthesis, structure–activity relationship, kinetics and molecular docking studies of non-cytotoxic benzamide derivatives as selective butyrylcholinesterase inhibitors},
journal = {Bioorganic & Medicinal Chemistry},
volume = {27},
number = {18},
pages = {4030-4040},
year = {2019},
issn = {0968-0896},
doi = {https://doi.org/10.1016/j.bmc.2019.07.015},
url = {https://www.sciencedirect.com/science/article/pii/S0968089619309277},
author = {Sheeba Wajid and Asma Khatoon and Maria Aqeel Khan and Humaira Zafar and Shama Kanwal and  Atta-ur-Rahman and M. Iqbal Choudhary and Fatima Z. Basha},
keywords = {Benzamides, Green chemistry, Microwave-Assisted Organic Synthesis, Acetylcholinesterase, Butyrylcholinesterase, Enzyme inhibition, Alzheimer disease},
abstract = {A series of benzamide derivatives 1–12 with various functional groups (–H, –Br, –F, –OCH3, –OC2H5, and –NO2) was synthesized using an economic, and facile Microwave-Assisted Organic Synthesis, and evaluated for acetylcholinesterase (ACHE) and butyrylcholinesterase (BCHE) activity in vitro. Structure–activity relationship showed that the substitution of –Br group influenced the inhibitory activity against BCHE enzyme. Synthesized compounds were found to be selective inhibitors of BCHE. In addition, all compounds 1–12 were found to be non-cytotoxic, as compared to the standard cycloheximide (IC50 = 0.8 ± 0.2 µM). Among them, compound 3 revealed the most potent BCHE inhibitory activity (IC50 = 0.8 ± 0.6 µM) when compared with the standard galantamine hydrobromide (IC50 = 40.83 ± 0.37 µM). Enzyme kinetic studies indicated that compounds 1, 3–4, and 7–8 showed a mixed mode of inhibition against BCHE, while compounds 2, 5–6 and 9 exhibited an uncompetitive pattern of inhibition. Molecular docking studies further highlighted the interaction of these inhibitors with catalytically important amino acid residues, such as Glu197, Hip438, Phe329, and many others.}
}
@article{THOMSEN2015i78,
title = {Awareness during emergence from anaesthesia: significance of neuromuscular monitoring in patients with butyrylcholinesterase deficiency},
journal = {British Journal of Anaesthesia},
volume = {115},
pages = {i78-i88},
year = {2015},
issn = {0007-0912},
doi = {https://doi.org/10.1093/bja/aev096},
url = {https://www.sciencedirect.com/science/article/pii/S0007091217310139},
author = {J.L. Thomsen and C.V. Nielsen and K.Z. Eskildsen and M.N. Demant and M.R. Gätke},
keywords = {anaesthesia awareness, butyrylcholinesterase deficiency, neuromuscular block, neuromuscular monitoring},
abstract = {Background
Butyrylcholinesterase deficiency can result in prolonged paralysis after administration of succinylcholine or mivacurium. We conducted an interview study to assess whether patients with butyrylcholinesterase deficiency were more likely to have experienced awareness during emergence from anaesthesia if neuromuscular monitoring had not been applied.
Methods
Patients referred during 2004–2012 were included. Data on the use of neuromuscular monitoring were available from a previous study. Interviews, conducted by telephone, included questions about awareness and screening for post-traumatic stress disorder. Reports of panic, hopelessness, suffocation, or a feeling of being dead or dying resulted in the experience being classified further as distressful. Patients were categorized as aware or unaware by investigators blinded to use of neuromuscular monitoring.
Results
Ninety-five patients were eligible to be interviewed. Of the 70 patients interviewed, 35 (50%) were aware while paralysed during emergence. Of these, 28 (80%) were not monitored with a nerve stimulator when awakened, compared with 17 (49%) of the 35 unaware patients (P=0.012, Fisher’s exact test). Thirty (86%) aware patients reported distress compared with seven (20%) unaware patients (P<0.001). The aware patients scored higher in screening for post-traumatic stress disorder (P=0.006, Mann–Whitney U-test).
Conclusions
Butyrylcholinesterase deficiency is a major risk factor for distressing awareness during emergence. Lack of neuromuscular monitoring increases the risk significantly. Neuromuscular monitoring should be applied even when using short-acting neuromuscular blocking agents.}
}
@article{ERDEMIR2018797,
title = {2-Hydroxyethyl substituted NHC precursors: Synthesis, characterization, crystal structure and carbonic anhydrase, α-glycosidase, butyrylcholinesterase, and acetylcholinesterase inhibitory properties},
journal = {Journal of Molecular Structure},
volume = {1155},
pages = {797-806},
year = {2018},
issn = {0022-2860},
doi = {https://doi.org/10.1016/j.molstruc.2017.11.079},
url = {https://www.sciencedirect.com/science/article/pii/S0022286017315673},
author = {Fatoş Erdemir and Duygu {Barut Celepci} and Aydın Aktaş and Parham Taslimi and Yetkin Gök and Hasan Karabıyık and İlhami Gülçin},
keywords = {-heterocyclic carbenes, Carbonic anhydrase, Cholinesterase, α-Glycosidase, X-ray diffraction},
abstract = {This study contains novel a serie synthesis of N-heterocyclic carbene (NHC) precursors that 2-hydroxyethyl substituted. The NHC precursors have been prepared from 1-(2- hydroxyethyl)benzimidazole and alkyl halides. The novel NHC precursors have been characterized by using 1H NMR, 13C NMR, FTIR spectroscopy and elemental analysis techniques. Molecular and crystal structures of 2a, 2d, 2e, 2f and 2g were obtained with single-crystal X-ray diffraction studies. These novel NHC precursor's derivatives effectively inhibited the α-glycosidase, cytosolic carbonic anhydrase I and II isoforms (hCA I and II), butyrylcholinesterase (BChE) and acetylcholinesterase (AChE). Inhibition constant (Ki) were found in the range of 0.30–9.22 nM for α-glycosidase, 13.90–41.46 nM for hCA I, 12.82–49.95 nM for hCA II, 145.82–882.01 nM for BChE, and 280.92–1370.01 nM for AChE, respectively.}
}
@article{JASIECKI2019154,
title = {Haplotypes of butyrylcholinesterase K-variant and their influence on the enzyme activity},
journal = {Chemico-Biological Interactions},
volume = {307},
pages = {154-157},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.05.007},
url = {https://www.sciencedirect.com/science/article/pii/S0009279718314364},
author = {Jacek Jasiecki and Monika Żuk and Natalia Krawczyńska and Joanna Jońca and Anna Szczoczarz and Krzysztof Lewandowski and Krzysztof Waleron and Bartosz Wasąg},
keywords = {BChE, Butyrylcholinesterase, Pseudocholinesterase, K-variant, Gene polymorphisms},
abstract = {Butyrylcholinesterase (BChE) is a serine hydrolase widely distributed throughout the body. It provides protection against administrated or inhaled poisons by hydrolyzing or sequestering the toxic compounds. The most frequent genetic variant of BCHE gene – K variant (p.A539T) is located in the C-terminal tetramerization domain, outside of the catalytic center. Many studies tried to reveal the nature of the lower activity of BChE K-variant but results and conclusions were often contradictory. The aim of this study is to estimate K allele frequency and its coexisting alterations in BCHE gene in a population of 162 individuals, as well as, assess influence on the enzyme activity in serum. We present three haplotypes of BChE-K variant, two of them coexist in strong linkage disequilibrium with alterations in 5′UTR (rs1126680), intron 2 (rs55781031) or in exon 2 (rs1799807). We demonstrate a negative role of these alterations on enzyme activity. By oneself BCHE-K (with no other alterations in BCHE gene) haplotype exhibits wild type enzyme activity. Based on our previous and presented results we conclude that SNPs localized outside the coding sequence, in 5′UTR or/and in intron 2 of BCHE gene, but not solely in K-variant alteration (p.A539T) itself, are responsible for reduced enzyme activity.}
}
@article{KHAN2008231,
title = {Pharmacological effects of a novel isosorbide-based butyrylcholinesterase inhibitor},
journal = {Chemico-Biological Interactions},
volume = {175},
number = {1},
pages = {231-234},
year = {2008},
note = {Proceedings of the IX International Meeting on Cholinesterases},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2008.05.024},
url = {https://www.sciencedirect.com/science/article/pii/S000927970800286X},
author = {D. Khan and J.F. Gilmer and C.G. Carolan and J.M. Gaynor and S.A. Ryder},
keywords = {Butyrylcholinesterase, Inhibition, Carboxylesterase, Hydrolysis},
abstract = {Isosorbide-2-benzylcarbamate-5-benzoate, a novel butyrylcholinesterase inhibitor, shows interspecies variation in its inhibitory activity (IC50 of 4.3nM for human plasma butyrylcholinesterase, but 1.09μM for mouse plasma butyrylcholinesterase). Stability studies revealed that this drug is resistant to hydrolysis by human plasma (no degradation in 1h). However, it was found to undergo rapid degradation when incubated with mouse plasma or mouse liver homogenate, yielding benzyl carbamate and benzoic acid. The addition of the carboxylesterase inhibitor bis-(4-nitrophenyl) phosphate (BNPP) inhibited the degradation of the novel drug, indicating that it may be a substrate for both butyrylcholinesterase and carboxylesterase. The absence of carboxylesterase from human plasma explains the drug's stability in this medium. In vivo, pharmacodynamic studies on single doses of 1mg/kg to naïve male C57BL/6 mice revealed maximal plasma butyrylcholinesterase inhibition 20min after intraperitoneal administration (∼60% inhibition) and 1h after administration by gavage (∼45% inhibition). While this plasma butyrylcholinesterase inhibition was short-lived, the drug also penetrated the blood–brain barrier resulting in a slight (10–15%) but persistent (≥72h) reduction in brain butyrylcholinesterase activity.}
}
@article{DARVESH20102232,
title = {Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants},
journal = {Bioorganic & Medicinal Chemistry},
volume = {18},
number = {6},
pages = {2232-2244},
year = {2010},
issn = {0968-0896},
doi = {https://doi.org/10.1016/j.bmc.2010.01.066},
url = {https://www.sciencedirect.com/science/article/pii/S0968089610000970},
author = {Sultan Darvesh and Ian R. Pottie and Katherine V. Darvesh and Robert S. McDonald and Ryan Walsh and Sarah Conrad and Andrea Penwell and Diane Mataija and Earl Martin},
keywords = {Acetylcholinesterase, Butyrylcholinesterase, Enzyme kinetics, Mutant butyrylcholinesterase},
abstract = {A series of N-10 urea derivatives of phenothiazine was synthesized and each compound was evaluated for its ability to inhibit human cholinesterases. Most were specific inhibitors of BuChE. However, the potent inhibitory effects on both cholinesterases of one sub-class, the cationic aminoureas, provide an additional binding mechanism to cholinesterases for these compounds. The comparative effects of aminoureas on wild-type BuChE and several BuChE mutants indicate a binding process involving salt linkage with the aspartate of the cholinesterase peripheral anionic site. The effect of such compounds on cholinesterase activity at high substrate concentration supports ionic interaction of aminoureas at the peripheral anionic site.}
}
@article{WU2020115324,
title = {Design, synthesis and biological evaluation of novel carbamates as potential inhibitors of acetylcholinesterase and butyrylcholinesterase},
journal = {Bioorganic & Medicinal Chemistry},
volume = {28},
number = {5},
pages = {115324},
year = {2020},
issn = {0968-0896},
doi = {https://doi.org/10.1016/j.bmc.2020.115324},
url = {https://www.sciencedirect.com/science/article/pii/S0968089619319431},
author = {Jie Wu and Marco Pistolozzi and Siyu Liu and Wen Tan},
keywords = {Carbamates, Acetylcholinesterase, Butyrylcholinesterase, Inhibitor, Bambuterol},
abstract = {Rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), has been approved by U.S. Food and Drug Administration to treat Alzheimer’s disease (AD) and Parkinson’s disease (PD) dementia. In the current work, a bambuterol derivative lacking one of the carbamoyloxy groups on the benzene ring (BMC-1) and its analogues were synthesized using 1-(3-hydroxyphenyl) ethan-1-one and 1-(4-hydroxyphenyl) ethan-1-one as starting materials. In-vitro cholinesterase assay established that nine compounds were more potent to inhibit both electric eel AChE and equine serum BChE than rivastigmine under the same experimental conditions. Further study confirmed that among the nine carbamates, BMC-3 (IC50(AChE) = 792 nM, IC50(BChE) = 2.2 nM) and BMC-16 (IC50(AChE) = 266 nM, IC50(BChE) = 10.6 nM) were excellent cholinesterase inhibitors with potential of permeating through the blood-brain barrier. These carbamates could be used as potential dual inhibitors of AChE and BChE and to discover novel drugs for the treatment of AD and PD dementia.}
}
@article{MUGHAL2019103124,
title = {Flavonols and 4-thioflavonols as potential acetylcholinesterase and butyrylcholinesterase inhibitors: Synthesis, structure-activity relationship and molecular docking studies},
journal = {Bioorganic Chemistry},
volume = {91},
pages = {103124},
year = {2019},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2019.103124},
url = {https://www.sciencedirect.com/science/article/pii/S004520681930745X},
author = {Ehsan Ullah Mughal and Amina Sadiq and Jamshaid Ashraf and Muhammad Naveed Zafar and Sajjad Hussain Sumrra and Rubina Tariq and Amara Mumtaz and Asif Javid and Bilal Ahmad Khan and Anser Ali and Chaudhary Omer Javed},
keywords = {Flavonoids, Flavonols, 3-hydroxyflavones, 4-thioflavonols, Sulfur compounds, Cholinesterases, AChE/BChE inhibitors, Molecular docking studies},
abstract = {To explore new scaffolds for the treat of Alzheimer’s disease appears to be an inspiring goal. In this context, a series of varyingly substituted flavonols and 4-thioflavonols have been designed and synthesized efficiently. All the newly synthesized compounds were characterized unambiguously by common spectroscopic techniques (IR, 1H-, 13C NMR) and mass spectrometry (EI-MS). All the derivatives (1–24) were evaluated in vitro for their inhibitory potential against cholinesterase enzymes. The results exhibited that these derivatives were potent selective inhibitors of acetylcholinesterase (AChE), except the compound 11 which was selective inhibitor of butyrylcholinesterase (BChE), with varying degree of IC50 values. Remarkably, the compounds 20 and 23 have been found the most potent almost dual inhibitors of AChE and BChE amongst the series with IC50 values even less than the standard drug. The experimental results in silico were further validated by molecular docking studies in order to find their binding modes with the active pockets of AChE and BChE enzymes.}
}
@article{MA2021106220,
title = {Sensitive detection of butyrylcholinesterase activity based on a separation-free photothermal assay},
journal = {Microchemical Journal},
volume = {166},
pages = {106220},
year = {2021},
issn = {0026-265X},
doi = {https://doi.org/10.1016/j.microc.2021.106220},
url = {https://www.sciencedirect.com/science/article/pii/S0026265X21003040},
author = {Zerui Ma and Lili Cao and Yifei Xing and Anrui Feng and Peng Zhang and Wei Li and Hailiang Nie and Yu-e Shi and Zhenguang Wang},
keywords = {Butyrylcholinesterase, Photothermal assay, Separation-free, Polydopamine, MnO nanosheets},
abstract = {Butyrylcholinesterase (BChE), a regulator for the cholinesterase activity in serum, is an important index for clinical diagnosis of organophosphorus poisoning and liver related disease. However, the assays for BChE activity are highly dependent on expensive and bulk equipment and professional operators, which limits its straightforward and portable detection. In this work, we proposed a straightforward and sensitive photothermal assay for the detection of BChE activity, avoiding the use of expensive instrument, professional operators, and separation process. Polydopamine (PDA) nanoparticles can be produced through the oxidation of dopamine by MnO2 nanosheets, which show a rather strong photothermal features. Hydrolyzation of substrate into thiocholine and butyrate happens after introducing BChE. The generated thiocholine and butyrate inhibit the formation of PDA nanoparticle through reducing MnO2 into Mn2+ and creating an acidic environment, respectively. Those effects lead to the decreasing of photothermal efficiency of the reaction system, resulting in the decreasing on temperature change. Quantitative detection of BChE activity is achieved by recording the temperature change of system, using a common device, with a limit of detection of 40.65 U/L calculated. The presented results provide a clue for developing straightforward and portable photothermal assay for BChE, which shows great potential for their clinical applications.}
}
@article{DEBAY2017166,
title = {Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease},
journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
volume = {3},
number = {2},
pages = {166-176},
year = {2017},
issn = {2352-8737},
doi = {https://doi.org/10.1016/j.trci.2017.01.005},
url = {https://www.sciencedirect.com/science/article/pii/S2352873717300057},
author = {Drew R. DeBay and George A. Reid and Ian R. Pottie and Earl Martin and Chris V. Bowen and Sultan Darvesh},
keywords = {Alzheimer's disease, Butyrylcholinesterase, Acetylcholinesterase, Single-photon emission computed tomography, Molecular imaging, Neuroimaging, Iodine, Alzheimer mouse model with 5 familial mutations},
abstract = {Introduction
Diagnosis of Alzheimer's disease (AD) in vivo, by molecular imaging of amyloid or tau, is constrained because similar changes can be found in brains of cognitively normal individuals. Butyrylcholinesterase (BChE), which becomes associated with these structures in AD, could elevate the accuracy of AD diagnosis by focusing on BChE pathology in the cerebral cortex, a region of scant BChE activity in healthy brain.
Methods
N-methylpiperidin-4-yl 4-[123I]iodobenzoate, a BChE radiotracer, was injected intravenously into B6SJL-Tg(APPSwFlLon, PSEN1∗M146 L∗L286 V) 6799Vas/Mmjax (5XFAD) mice and their wild-type (WT) counterparts for comparative single photon emission computed tomography (SPECT) studies. SPECT, computed tomography (CT), and magnetic resonance imaging (MRI) enabled comparison of whole brain and regional retention of the BChE radiotracer in both mouse strains.
Results
Retention of the BChE radiotracer was consistently higher in the 5XFAD mouse than in WT, and differences were particularly evident in the cerebral cortex.
Discussion
Cerebral cortical BChE imaging with SPECT can distinguish 5XFAD mouse model from the WT counterpart.}
}
@article{IQBAL2019108735,
title = {Reactivation potency of two novel oximes (K456 and K733) against paraoxon-inhibited acetyl and butyrylcholinesterase: In silico and in vitro models},
journal = {Chemico-Biological Interactions},
volume = {310},
pages = {108735},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.108735},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719300328},
author = {Amna Iqbal and Shahrukh Malik and Syed M. Nurulain and Kamil Musilek and Kamil Kuca and Huba Kalasz and M. Qaiser Fatmi},
abstract = {Organophosphates (OPs) irreversibly inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes. The reactivation of these inhibited enzymes is paramount for their normal function. Present study evaluates reactivation potency of two newly developed oximes, K456 and K733, against paraoxon (POX)-inhibited human-RBC-AChE and human-plasma-BChE in comparison to reported reactivator, pralidoxime (2-PAM). In vitro studies showed higher intrinsic toxicities of both oximes than 2-PAM for AChE. No substantial reactivation of hBChE was noted by tested concentration. Contrary to 2-PAM, the in silico study predicted lower binding free energies for both oximes. However, the detailed interaction study revealed inability of oximes to interact with catalytic anionic site of AChE and hBChE in contrast to 2-PAM. Both in vitro and in silico studies conclude that K456 and K733 are unlikely to be used as reactivators of paraoxon-inhibited AChE or BChE.}
}
@article{MASSON2010107,
title = {Butyrylcholinesterase for protection from organophosphorus poisons: Catalytic complexities and hysteretic behavior},
journal = {Archives of Biochemistry and Biophysics},
volume = {494},
number = {2},
pages = {107-120},
year = {2010},
issn = {0003-9861},
doi = {https://doi.org/10.1016/j.abb.2009.12.005},
url = {https://www.sciencedirect.com/science/article/pii/S0003986109004056},
author = {Patrick Masson and Oksana Lockridge},
keywords = {Bioscavenger, Mass spectrometry, Phosphylation, Dehydroalanine, Aryl acylamidase, Hysteresis},
abstract = {Butyrylcholinesterase is a promiscuous enzyme that displays complex kinetic behavior. It is toxicologically important because it detoxifies organophosphorus poisons (OP) by making a covalent bond with the OP. The OP and the butyrylcholinesterase are both inactivated in the process. Inactivation of butyrylcholinesterase has no adverse effects. However, inactivation of acetylcholinesterase in nerve synapses can be lethal. OP-inhibited butyrylcholinesterase and acetylcholinesterase can be reactivated with oximes provided the OP has not aged. Strategies for preventing the toxicity of OP include (a) treatment with an OP scavenger, (b) reaction of non-aged enzyme with oximes, (c) reactivation of aged enzyme, (d) slowing down aging with peripheral site ligands, and (e) design of mutants that rapidly hydrolyze OP. Option (a) has progressed through phase I clinical trials with human butyrylcholinesterase. Option (b) is in routine clinical use. The others are at the basic research level. Butyrylcholinesterase displays complex kinetic behavior including activation by positively charged esters, ability to hydrolyze amides, and a lag time (hysteresis) preceding hydrolysis of benzoylcholine and N-methylindoxyl acetate. Mass spectrometry has identified new OP binding motifs on tyrosine and lysine in proteins that have no active site serine. It is proposed, but not yet proven, that low dose exposure involves OP modification of proteins that have no active site serine.}
}
@article{STOJAN2019350,
title = {The mechanism and benefit of human butyrylcholinesterase activation by what would otherwise be inhibitors},
journal = {Chemico-Biological Interactions},
volume = {308},
pages = {350-356},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.06.005},
url = {https://www.sciencedirect.com/science/article/pii/S000927971930136X},
author = {Jure Stojan},
keywords = {Cholinesterases, Kinetics, Reactivation, Aged enzyme},
abstract = {Activation of human butyrylcholinesterase by small quaternary ammonium ions is known. Here, additional ligands in this series are presented: edrophonium and choline, and the reactivator pyridine-2-aldoxime methochloride. Kinetic analysis of the progress curves with these compounds indicates the mechanism of enhanced deacylation by the ligand bound to the catalytic anionic site (Trp82) at the base of the active site. The larger, bis-quaternary ligands examined, as propidium, hexamethonium, decamethonium, and bis-thiocholine, show only competitive inhibition of butyrylcholinesterase, by preventing substrate approach. This hypothesis of enhanced deacylation was tested for reactivation of methanesulfonylfluoride-inactivated butyrylcholinesterase, a complex analogous to organophosphate-aged cholinesterases. The combination of substrate/products and pyridine-2-aldoxime methochloride improved butyrylcholinesterase activity over 2 h of continuous measurements, before which time substrate depletion prevailed. Similar reactivation of Torpedo californica acetylcholinesterase was unsuccessful, but both of these cholinesterases regain some activity if they have been inhibited and aged for days by diisopropylfluorophosphate.}
}
@article{SAEED2017204,
title = {Design, synthesis, molecular docking studies of organotin-drug derivatives as multi-target agents against antibacterial, antifungal, α-amylase, α-glucosidase and butyrylcholinesterase},
journal = {Inorganica Chimica Acta},
volume = {464},
pages = {204-213},
year = {2017},
issn = {0020-1693},
doi = {https://doi.org/10.1016/j.ica.2017.05.036},
url = {https://www.sciencedirect.com/science/article/pii/S002016931730097X},
author = {Aamer Saeed and Pervaiz Ali Channar and Fayaz Ali Larik and Farukh Jabeen and Urooj Muqadar and Shomaila Saeed and Ulrich Flörke and Hammad Ismail and Erum Dilshad and Bushra Mirza},
keywords = {Synthesis, Organotin, Drug-derivatives, α-Amylase, α-Glucosidase and butyrylcholinesterase, Antifungal, Antibacterial, Molecular docking},
abstract = {A series of organotin esters has been synthesized using a diverse array of drugs containing carboxylic function with triphenyl/tributyltin. The synthesized derivatives were bioevaluated for antibacterial, antifungal and enzyme inhibition (α-amylase, α-glucosidase and butyrylcholinesterase) activities. Interestingly, compound 3c was found to be most potent in all bioassay and showed higher activity than the standards in case of antibacterial and antifungal activity. The molecular docking was utilized to ascertain the mechanism and mode of action towards the molecular targets indicating that ligands and complexes were stabilized at the active site by electrostatic and hydrophobic forces, consistent with the corresponding experimental results. Docking simulation providing additional information about the possibilities of the inhibitory potential of the compounds against the 1j7t and 1EA1. It has been predicted by in silico calculation and investigation of the binding pattern that compound 3c can serve as the potential surrogate for hit to lead generation and design of novel antibacterial and anti-leishmanial agents.}
}
@article{OZTASKIN2017104,
title = {Novel antioxidant bromophenols with acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase inhibitory actions},
journal = {Bioorganic Chemistry},
volume = {74},
pages = {104-114},
year = {2017},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2017.07.010},
url = {https://www.sciencedirect.com/science/article/pii/S0045206817304418},
author = {Necla Öztaskın and Parham Taslimi and Ahmet Maraş and İlhami Gülcin and Süleyman Göksu},
keywords = {Bromophenols, Antioxidant activity, Acetylcholinesterase, Butyrylcholinesterase, Carbonic anhydrase},
abstract = {In this study, a series of novel bromophenols were synthesized from benzoic acids and methoxylated bromophenols. The synthesized compounds were evaluated by using different bioanalytical antioxidant assays including 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) (ABTS+) radical scavenging assays. Also, reducing power of novel bromophenols were evaluated by Cu2+-Cu+ reducing, Fe3+-Fe2+ reducing and [Fe3+-(TPTZ)2]3+-[Fe2+-(TPTZ)2]2+ reducing and ferrous ions (Fe2+) chelating abilities. The compounds demonstrate powerful antioxidant activities when compared to standard antioxidant molecules of α-tocopherol, trolox, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT). Also in the last part of this studies novel bromophenols were tested against some metabolic enzymes including acetylcholinesterase (AChE), butyrylcholinesterase (BChE) enzymes and carbonic anhydrase I, and II (hCA I and hCA II) isoenzymes. The newly synthesized bromophenols showed Ki values in a range of 6.78±0.68 to 126.07±35.6nM against hCA I, 4.32±0.23 to 72.25±12.94nM against hCA II, 4.60±1.15 to 38.13±5.91nM against AChE and 7.36±1.31 to 29.38±3.68nM against BChE.}
}
@article{MARYAMABADI20161408,
title = {Application of PEG-400 as a green biodegradable polymeric medium for the catalyst-free synthesis of spiro-dihydropyridines and their use as acetyl and butyrylcholinesterase inhibitors},
journal = {Bioorganic & Medicinal Chemistry},
volume = {24},
number = {6},
pages = {1408-1417},
year = {2016},
issn = {0968-0896},
doi = {https://doi.org/10.1016/j.bmc.2016.02.019},
url = {https://www.sciencedirect.com/science/article/pii/S0968089616300992},
author = {Ammar Maryamabadi and Alireza Hasaninejad and Najmeh Nowrouzi and Gholamhossein Mohebbi and Behvar Asghari},
keywords = {Spiro-dihydropyridines, Multi-component reactions, Catalyst-free, Acetylcholinesterase inhibition, Butyrylcholinesterase inhibition},
abstract = {A simple, efficient and green approach for the synthesis of spiro-dihydropyridines derivatives by one-pot multi-component reaction of isatin or acenaphthoquinone derivatives (1equiv) with malononitrile (1equiv) and N,N′-substituted-2-nitroethene-1,1-diamines (1equiv) in PEG-400 under catalyst-free conditions is described. This method provides several advantages such as environmental friendliness, short reaction time, and simple workup procedure for the synthesis of biologically important compounds. The ability of synthesized compounds in inhibition of acetyl and butyrylcholinesterase were investigated both in vitro and in silico. All compounds showed moderate to high level activity against both acetyl and butyrylcholinesterase. There was a good correlation between in vitro and in silico studies.}
}
@article{ZAREI2021e06683,
title = {Design, synthesis and biological assessment of new 1-benzyl-4-((4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium derivatives (BOPs) as potential dual inhibitors of acetylcholinesterase and butyrylcholinesterase},
journal = {Heliyon},
volume = {7},
number = {4},
pages = {e06683},
year = {2021},
issn = {2405-8440},
doi = {https://doi.org/10.1016/j.heliyon.2021.e06683},
url = {https://www.sciencedirect.com/science/article/pii/S2405844021007866},
author = {Samaneh Zarei and Mohammad Shafiei and Maryam Firouzi and Loghman Firoozpour and Kouros Divsalar and Ali Asadipour and Tahmineh Akbarzadeh and Alireza Foroumadi},
keywords = {Alzheimer's disease, Chloinestrases, Oxoquinazolin, Pyridinuim salts, In-vitro assay},
abstract = {Alzheimer's disease (AD), is among the most growing neurodegenerative diseases, which is mainly caused by the acetylcholine neurotransmitter loss in the hippocampus and cortex. Emerging of the dual Acetylcholinesterase (AChE)/Butyrylcholinesterase (BuChE) inhibitors has increased for treating Alzheimer disease. In this study, we would like to report the design and synthesis of a new sequence of 1-benzyl-4-((4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium derivatives (BOPs) assessed as BuChE and AChE inhibitors. Ellman's approach was used for the evaluation of AChE and BuChE inhibitory activities. Moreover, docking research was conducted to predict the action mechanism. Among all synthesized compounds, 1-(3-bromobenzyl)-3-((4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium bromide (BOP-1) was found to be the most active compound with dual activity for inhibition of AChE (IC50 = 5.90 ± 0.07μM), and BuChE (IC50 = 6.76 ± 0.04μM) and 1-(4-chlorobenzyl)-3-((6,7-dimethoxy-4-oxoquinazolin-3(4H)-yl)methyl) pyridin-1-ium chloride (BOP-8) showed the highest AChE inhibitory activity (IC50s = 1.11 ± 0.09 μM). The synthesized compounds BOP-1 and BOP-8 could be proposed as valuable lead compounds for further drug discovery development against AD.}
}
@article{BAJDA201829,
title = {Novel carbamate derivatives as selective butyrylcholinesterase inhibitors},
journal = {Bioorganic Chemistry},
volume = {78},
pages = {29-38},
year = {2018},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2018.03.003},
url = {https://www.sciencedirect.com/science/article/pii/S0045206817308453},
author = {Marek Bajda and Kamil Łątka and Michalina Hebda and Jakub Jończyk and Barbara Malawska},
keywords = {Carbamates, Butyrylcholinesterase, Inhibitor, Synthesis, Biological evaluation, Physicochemical properties, Docking studies},
abstract = {Selective butyrylcholinesterase inhibitors could be the promising drug candidates, used in treatment of Alzheimer's disease. The study describes the synthesis and biological activity of novel carbamate derivatives with N-phenylpiperazine, N-benzylpiperazine and 4-benzylpiperidine moieties. Biological studies revealed that most of these compounds displayed significant activity against BuChE. Compound 16 (3-(4-phenyl-piperazin-1-ylmethyl)-phenyl phenylcarbamate) turned out to be the most active (IC50 = 2.00 μM for BuChE). For all synthesized compounds lipophilicity and other physicochemical properties were calculated using computer programs. Relationship between these properties and activity was also checked. Binding mode with enzyme and the ensuing differences in activity were explained by the molecular modeling studies.}
}
@article{ALTAF2017130,
title = {Ferrocenylaniline based amide analogs of methoxybenzoic acids: Synthesis, structural characterization and butyrylcholinesterase (BChE) inhibition studies},
journal = {Journal of Molecular Structure},
volume = {1146},
pages = {130-137},
year = {2017},
issn = {0022-2860},
doi = {https://doi.org/10.1016/j.molstruc.2017.05.132},
url = {https://www.sciencedirect.com/science/article/pii/S0022286017307524},
author = {Ataf Ali Altaf and Samia Kausar and Muhammad Hamayun and Bhajan Lal and Muhammad Nawaz Tahir and Amin Badshah},
keywords = {Ferrocene, Amides, Crystal structure, Butyrylcholinesterase (BChE), Docking},
abstract = {Three new ferrocene based amides were synthesized with slight structural difference. The general formula of the amides is C5H5FeC5H4C6H4NHCOC6H4(OCH3). The synthesized compounds were characterized by instrumental techniques like elemental analysis, FTIR and NMR spectroscopy. Structure of the two compounds was also studied by single crystal X-rays diffraction analysis. Structural studies provide the evidence that pMeO (one of the synthesized compounds) is an example of amides having no intermolecular hydrogen bonding in solid structure. In the BChE inhibition assay, compound (oMeO) having strong intermolecular force in the solid structure is less active than the compound (pMeO) with weak intermolecular forces in the solid structure. The docking studies proved that hydrogen bonding between inhibitor and BChE enzyme is of more importance for the activity, rather than intermolecular hydrogen bonding in the solid structure of inhibitor.}
}
@incollection{DEBAY2020263,
title = {Chapter 17 - Butyrylcholinesterase as a biomarker in Alzheimer’s disease},
editor = {Colin R. Martin and Victor R. Preedy},
booktitle = {Diagnosis and Management in Dementia},
publisher = {Academic Press},
pages = {263-280},
year = {2020},
isbn = {978-0-12-815854-8},
doi = {https://doi.org/10.1016/B978-0-12-815854-8.00017-3},
url = {https://www.sciencedirect.com/science/article/pii/B9780128158548000173},
author = {Drew R. DeBay and Sultan Darvesh},
keywords = {Acetylcholinesterase, Alzheimer disease, Biomarker, Butyrylcholinesterase, Cerebral spinal fluid, Cholinergic system, Dementia, Neuroimaging, Positron emission tomography, Single photon emission computed tomography},
abstract = {Alzheimer disease (AD) is the most common neurodegenerative disorder that causes dementia and is a significant cause of morbidity and mortality. The etiology of AD remains unknown and a definitive diagnosis is not yet achievable for the disease during life. As a consequence, intense focus has been placed on establishing reliable AD biomarkers that both improve the certainty of an AD diagnosis during life and improve our understanding of the pathogenesis of the disease. In this chapter we explore biomarkers currently being evaluated in AD. Components of the central cholinergic system will be emphasized, especially highlighting the enzyme butyrylcholinesterase as an important diagnostic biomarker in AD.}
}
@article{PURGATORIO2019414,
title = {Investigating 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole as scaffold of butyrylcholinesterase-selective inhibitors with additional neuroprotective activities for Alzheimer's disease},
journal = {European Journal of Medicinal Chemistry},
volume = {177},
pages = {414-424},
year = {2019},
issn = {0223-5234},
doi = {https://doi.org/10.1016/j.ejmech.2019.05.062},
url = {https://www.sciencedirect.com/science/article/pii/S0223523419304799},
author = {Rosa Purgatorio and Modesto {de Candia} and Marco Catto and Antonio Carrieri and Leonardo Pisani and Annalisa {De Palma} and Maddalena Toma and Olga A. Ivanova and Leonid G. Voskressensky and Cosimo D. Altomare},
keywords = {Alzheimer's disease, Azepino[4,3-]indole, Acetylcholinesterase, Butyrylcholinesterase, Amyloid-β aggregation, Neuroprotection},
abstract = {Due to the role of butyrylcholinesterase (BChE) in acetylcholine hydrolysis in the late stages of the Alzheimer's disease (AD), inhibitors of butyrylcholinesterase (BChE) have been recently envisaged, besides acetylcholinesterase (AChE) inhibitors, as candidates for treating mild-to-moderate AD. Herein, synthesis and AChE/BChE inhibition activity of some twenty derivatives of 1,2,3,4,5,6-hexahydroazepino[4,3-b]indole (HHAI) is reported. Most of the newly synthesized HHAI derivatives achieved the inhibition of both ChE isoforms with IC50s in the micromolar range, with a structure-dependent selectivity toward BChE. Apparently, molecular volume and lipophilicity do increase selectivity toward BChE, and indeed the N2-(4-phenylbutyl) HHAI derivative 15d, which behaves as a mixed-type inhibitor, resulted the most potent (IC50 0.17 μM) and selective (>100-fold) inhibitor toward either horse serum and human BChE. Moreover, 15d inhibited in vitro self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide and displayed neuroprotective effects in neuroblastoma SH-SY5Y cell line, significantly recovering (P < 0.001) cell viability when impaired by Aβ1-42 and hydrogen peroxide insults. Overall, this study highlighted HHAI as useful and versatile scaffold for developing new small molecules targeting some enzymes and biochemical pathways involved in the pathogenesis of AD.}
}
@article{GRIGORENKO2019138,
title = {Computer-designed active human butyrylcholinesterase double mutant with a new catalytic triad},
journal = {Chemico-Biological Interactions},
volume = {306},
pages = {138-146},
year = {2019},
issn = {0009-2797},
doi = {https://doi.org/10.1016/j.cbi.2019.04.019},
url = {https://www.sciencedirect.com/science/article/pii/S0009279719304016},
author = {Bella L. Grigorenko and Dana A. Novichkova and Sofya V. Lushchekina and Irina V. Zueva and Lawrence M. Schopfer and Alexander V. Nemukhin and Sergey D. Varfolomeev and Oksana Lockridge and Patrick Masson},
keywords = {Butyrylcholinesterase, Computer-designed enzyme, Catalytic triad, QM/MM, Molecular dynamics, Markov state model, Organophosphate inhibition/reactivation},
abstract = {A computer-designed mutant of human butyrylcholinesterase (BChE), N322E/E325G, with a novel catalytic triad was made. The catalytic triad of the wild-type enzyme (S198·H438·E325) was replaced by S198·H438·N322E in silico. Molecular dynamics for 1.5 μs and Markov state model analysis showed that the new catalytic triad should be operative in the mutant enzyme, suggesting functionality. QM/MM modeling performed for the reaction of wild-type BChE and double mutant with echothiophate showed high reactivity of the mutant towards the organophosphate. A truncated monomeric (L530 stop) double mutant was expressed in Expi293 cells. Non-purified transfected cell culture medium was analyzed. Polyacrylamide gel electrophoresis under native conditions followed by activity staining with BTC as the substrate provided evidence that the monomeric BChE mutant was active. Inhibition of the double mutant by echothiophate followed by polyacrylamide gel electrophoresis and activity staining showed that this enzyme slowly self-reactivated. However, because Expi293 cells secrete an endogenous BChE tetramer and several organophosphate-reacting enzymes, catalytic parameters and self-reactivation constants after phosphorylation of the new mutant were not determined in the crude cell culture medium. The study shows that the computer-designed double mutant (N322E/E325G) with a new catalytic triad (S198·H438·N322E) is a suitable template for design of novel active human BChE mutants that display an organophosphate hydrolase activity.}
}
@article{RAHIM2015106,
title = {Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease},
journal = {Bioorganic Chemistry},
volume = {62},
pages = {106-116},
year = {2015},
issn = {0045-2068},
doi = {https://doi.org/10.1016/j.bioorg.2015.08.002},
url = {https://www.sciencedirect.com/science/article/pii/S0045206815300110},
author = {Fazal Rahim and Muhammad Tariq Javed and Hayat Ullah and Abdul Wadood and Muhammad Taha and Muhammad Ashraf and  Qurat-ul-Ain and Muhammad Anas Khan and Fahad Khan and Salma Mirza and Khalid M. Khan},
keywords = {Alzheimer’s disease, Acetylcholinesterase inhibition, Butyrylcholinesterase Inhibition, Thiazole, Synthesis, Molecular docking},
abstract = {A series of thirty (30) thiazole analogs were prepared, characterized by 1H NMR, 13C NMR and EI-MS and evaluated for Acetylcholinesterase and butyrylcholinesterase inhibitory potential. All analogs exhibited varied butyrylcholinesterase inhibitory activity with IC50 value ranging between 1.59±0.01 and 389.25±1.75μM when compared with the standard eserine (IC50, 0.85±0.0001μM). Analogs 15, 7, 12, 9, 14, 1, 30 with IC50 values 1.59±0.01, 1.77±0.01, 6.21±0.01, 7.56±0.01, 8.46±0.01, 14.81±0.32 and 16.54±0.21μM respectively showed excellent inhibitory potential. Seven analogs 15, 20, 19, 24, 28, 30 and 25 exhibited good acetylcholinesterase inhibitory potential with IC50 values 21.3±0.50, 35.3±0.64, 36.6±0.70, 44.81±0.81, 46.36±0.84, 48.2±0.06 and 48.72±0.91μM respectively. All other analogs also exhibited well to moderate enzyme inhibition. The binding mode of these compounds was confirmed through molecular docking.}
}